537 results on '"Niclou, Simone P'
Search Results
2. Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence
- Author
-
Oudin, Anais, Moreno-Sanchez, Pilar M., Baus, Virginie, Niclou, Simone P., and Golebiewska, Anna
- Published
- 2024
- Full Text
- View/download PDF
3. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts
- Author
-
Yahaya A. Yabo, Pilar M. Moreno-Sanchez, Yolanda Pires-Afonso, Tony Kaoma, Bakhtiyor Nosirov, Andrea Scafidi, Luca Ermini, Anuja Lipsa, Anaïs Oudin, Dimitrios Kyriakis, Kamil Grzyb, Suresh K. Poovathingal, Aurélie Poli, Arnaud Muller, Reka Toth, Barbara Klink, Guy Berchem, Christophe Berthold, Frank Hertel, Michel Mittelbronn, Dieter H. Heiland, Alexander Skupin, Petr V. Nazarov, Simone P. Niclou, Alessandro Michelucci, and Anna Golebiewska
- Subjects
Glioblastoma ,Tumor microenvironment ,Myeloid cells ,Microglia ,Patient-derived orthotopic xenografts ,Single-cell RNA sequencing ,Medicine ,Genetics ,QH426-470 - Abstract
Abstract Background A major contributing factor to glioblastoma (GBM) development and progression is its ability to evade the immune system by creating an immune-suppressive environment, where GBM-associated myeloid cells, including resident microglia and peripheral monocyte-derived macrophages, play critical pro-tumoral roles. However, it is unclear whether recruited myeloid cells are phenotypically and functionally identical in GBM patients and whether this heterogeneity is recapitulated in patient-derived orthotopic xenografts (PDOXs). A thorough understanding of the GBM ecosystem and its recapitulation in preclinical models is currently missing, leading to inaccurate results and failures of clinical trials. Methods Here, we report systematic characterization of the tumor microenvironment (TME) in GBM PDOXs and patient tumors at the single-cell and spatial levels. We applied single-cell RNA sequencing, spatial transcriptomics, multicolor flow cytometry, immunohistochemistry, and functional studies to examine the heterogeneous TME instructed by GBM cells. GBM PDOXs representing different tumor phenotypes were compared to glioma mouse GL261 syngeneic model and patient tumors. Results We show that GBM tumor cells reciprocally interact with host cells to create a GBM patient-specific TME in PDOXs. We detected the most prominent transcriptomic adaptations in myeloid cells, with brain-resident microglia representing the main population in the cellular tumor, while peripheral-derived myeloid cells infiltrated the brain at sites of blood–brain barrier disruption. More specifically, we show that GBM-educated microglia undergo transition to diverse phenotypic states across distinct GBM landscapes and tumor niches. GBM-educated microglia subsets display phagocytic and dendritic cell-like gene expression programs. Additionally, we found novel microglial states expressing cell cycle programs, astrocytic or endothelial markers. Lastly, we show that temozolomide treatment leads to transcriptomic plasticity and altered crosstalk between GBM tumor cells and adjacent TME components. Conclusions Our data provide novel insights into the phenotypic adaptation of the heterogeneous TME instructed by GBM tumors. We show the key role of microglial phenotypic states in supporting GBM tumor growth and response to treatment. Our data place PDOXs as relevant models to assess the functionality of the TME and changes in the GBM ecosystem upon treatment. Graphical Abstract
- Published
- 2024
- Full Text
- View/download PDF
4. Federated Learning Enables Big Data for Rare Cancer Boundary Detection
- Author
-
Pati, Sarthak, Baid, Ujjwal, Edwards, Brandon, Sheller, Micah, Wang, Shih-Han, Reina, G Anthony, Foley, Patrick, Gruzdev, Alexey, Karkada, Deepthi, Davatzikos, Christos, Sako, Chiharu, Ghodasara, Satyam, Bilello, Michel, Mohan, Suyash, Vollmuth, Philipp, Brugnara, Gianluca, Preetha, Chandrakanth J, Sahm, Felix, Maier-Hein, Klaus, Zenk, Maximilian, Bendszus, Martin, Wick, Wolfgang, Calabrese, Evan, Rudie, Jeffrey, Villanueva-Meyer, Javier, Cha, Soonmee, Ingalhalikar, Madhura, Jadhav, Manali, Pandey, Umang, Saini, Jitender, Garrett, John, Larson, Matthew, Jeraj, Robert, Currie, Stuart, Frood, Russell, Fatania, Kavi, Huang, Raymond Y, Chang, Ken, Balana, Carmen, Capellades, Jaume, Puig, Josep, Trenkler, Johannes, Pichler, Josef, Necker, Georg, Haunschmidt, Andreas, Meckel, Stephan, Shukla, Gaurav, Liem, Spencer, Alexander, Gregory S, Lombardo, Joseph, Palmer, Joshua D, Flanders, Adam E, Dicker, Adam P, Sair, Haris I, Jones, Craig K, Venkataraman, Archana, Jiang, Meirui, So, Tiffany Y, Chen, Cheng, Heng, Pheng Ann, Dou, Qi, Kozubek, Michal, Lux, Filip, Michálek, Jan, Matula, Petr, Keřkovský, Miloš, Kopřivová, Tereza, Dostál, Marek, Vybíhal, Václav, Vogelbaum, Michael A, Mitchell, J Ross, Farinhas, Joaquim, Maldjian, Joseph A, Yogananda, Chandan Ganesh Bangalore, Pinho, Marco C, Reddy, Divya, Holcomb, James, Wagner, Benjamin C, Ellingson, Benjamin M, Cloughesy, Timothy F, Raymond, Catalina, Oughourlian, Talia, Hagiwara, Akifumi, Wang, Chencai, To, Minh-Son, Bhardwaj, Sargam, Chong, Chee, Agzarian, Marc, Falcão, Alexandre Xavier, Martins, Samuel B, Teixeira, Bernardo C A, Sprenger, Flávia, Menotti, David, Lucio, Diego R, LaMontagne, Pamela, Marcus, Daniel, Wiestler, Benedikt, Kofler, Florian, Ezhov, Ivan, Metz, Marie, Jain, Rajan, Lee, Matthew, Lui, Yvonne W, McKinley, Richard, Slotboom, Johannes, Radojewski, Piotr, Meier, Raphael, Wiest, Roland, Murcia, Derrick, Fu, Eric, Haas, Rourke, Thompson, John, Ormond, David Ryan, Badve, Chaitra, Sloan, Andrew E, Vadmal, Vachan, Waite, Kristin, Colen, Rivka R, Pei, Linmin, Ak, Murat, Srinivasan, Ashok, Bapuraj, J Rajiv, Rao, Arvind, Wang, Nicholas, Yoshiaki, Ota, Moritani, Toshio, Turk, Sevcan, Lee, Joonsang, Prabhudesai, Snehal, Morón, Fanny, Mandel, Jacob, Kamnitsas, Konstantinos, Glocker, Ben, Dixon, Luke V M, Williams, Matthew, Zampakis, Peter, Panagiotopoulos, Vasileios, Tsiganos, Panagiotis, Alexiou, Sotiris, Haliassos, Ilias, Zacharaki, Evangelia I, Moustakas, Konstantinos, Kalogeropoulou, Christina, Kardamakis, Dimitrios M, Choi, Yoon Seong, Lee, Seung-Koo, Chang, Jong Hee, Ahn, Sung Soo, Luo, Bing, Poisson, Laila, Wen, Ning, Tiwari, Pallavi, Verma, Ruchika, Bareja, Rohan, Yadav, Ipsa, Chen, Jonathan, Kumar, Neeraj, Smits, Marion, van der Voort, Sebastian R, Alafandi, Ahmed, Incekara, Fatih, Wijnenga, Maarten MJ, Kapsas, Georgios, Gahrmann, Renske, Schouten, Joost W, Dubbink, Hendrikus J, Vincent, Arnaud JPE, Bent, Martin J van den, French, Pim J, Klein, Stefan, Yuan, Yading, Sharma, Sonam, Tseng, Tzu-Chi, Adabi, Saba, Niclou, Simone P, Keunen, Olivier, Hau, Ann-Christin, Vallières, Martin, Fortin, David, Lepage, Martin, Landman, Bennett, Ramadass, Karthik, Xu, Kaiwen, Chotai, Silky, Chambless, Lola B, Mistry, Akshitkumar, Thompson, Reid C, Gusev, Yuriy, Bhuvaneshwar, Krithika, Sayah, Anousheh, Bencheqroun, Camelia, Belouali, Anas, Madhavan, Subha, Booth, Thomas C, Chelliah, Alysha, Modat, Marc, Shuaib, Haris, Dragos, Carmen, Abayazeed, Aly, Kolodziej, Kenneth, Hill, Michael, Abbassy, Ahmed, Gamal, Shady, Mekhaimar, Mahmoud, Qayati, Mohamed, Reyes, Mauricio, Park, Ji Eun, Yun, Jihye, Kim, Ho Sung, Mahajan, Abhishek, Muzi, Mark, Benson, Sean, Beets-Tan, Regina G H, Teuwen, Jonas, Herrera-Trujillo, Alejandro, Trujillo, Maria, Escobar, William, Abello, Ana, Bernal, Jose, Gómez, Jhon, Choi, Joseph, Baek, Stephen, Kim, Yusung, Ismael, Heba, Allen, Bryan, Buatti, John M, Kotrotsou, Aikaterini, Li, Hongwei, Weiss, Tobias, Weller, Michael, Bink, Andrea, Pouymayou, Bertrand, Shaykh, Hassan F, Saltz, Joel, Prasanna, Prateek, Shrestha, Sampurna, Mani, Kartik M, Payne, David, Kurc, Tahsin, Pelaez, Enrique, Franco-Maldonado, Heydy, Loayza, Francis, Quevedo, Sebastian, Guevara, Pamela, Torche, Esteban, Mendoza, Cristobal, Vera, Franco, Ríos, Elvis, López, Eduardo, Velastin, Sergio A, Ogbole, Godwin, Oyekunle, Dotun, Odafe-Oyibotha, Olubunmi, Osobu, Babatunde, Shu'aibu, Mustapha, Dorcas, Adeleye, Soneye, Mayowa, Dako, Farouk, Simpson, Amber L, Hamghalam, Mohammad, Peoples, Jacob J, Hu, Ricky, Tran, Anh, Cutler, Danielle, Moraes, Fabio Y, Boss, Michael A, Gimpel, James, Veettil, Deepak Kattil, Schmidt, Kendall, Bialecki, Brian, Marella, Sailaja, Price, Cynthia, Cimino, Lisa, Apgar, Charles, Shah, Prashant, Menze, Bjoern, Barnholtz-Sloan, Jill S, Martin, Jason, and Bakas, Spyridon
- Subjects
Computer Science - Machine Learning ,Electrical Engineering and Systems Science - Image and Video Processing - Abstract
Although machine learning (ML) has shown promise in numerous domains, there are concerns about generalizability to out-of-sample data. This is currently addressed by centrally sharing ample, and importantly diverse, data from multiple sites. However, such centralization is challenging to scale (or even not feasible) due to various limitations. Federated ML (FL) provides an alternative to train accurate and generalizable ML models, by only sharing numerical model updates. Here we present findings from the largest FL study to-date, involving data from 71 healthcare institutions across 6 continents, to generate an automatic tumor boundary detector for the rare disease of glioblastoma, utilizing the largest dataset of such patients ever used in the literature (25,256 MRI scans from 6,314 patients). We demonstrate a 33% improvement over a publicly trained model to delineate the surgically targetable tumor, and 23% improvement over the tumor's entire extent. We anticipate our study to: 1) enable more studies in healthcare informed by large and diverse data, ensuring meaningful results for rare diseases and underrepresented populations, 2) facilitate further quantitative analyses for glioblastoma via performance optimization of our consensus model for eventual public release, and 3) demonstrate the effectiveness of FL at such scale and task complexity as a paradigm shift for multi-site collaborations, alleviating the need for data sharing., Comment: federated learning, deep learning, convolutional neural network, segmentation, brain tumor, glioma, glioblastoma, FeTS, BraTS
- Published
- 2022
- Full Text
- View/download PDF
5. Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence
- Author
-
Anais Oudin, Pilar M. Moreno-Sanchez, Virginie Baus, Simone P. Niclou, and Anna Golebiewska
- Subjects
Glioblastoma ,Patient-derived orthotopic xenograft ,Brain surgery ,Tumor resection ,In vivo imaging ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Preclinical in vivo cancer models are essential tools for investigating tumor progression and response to treatment prior to clinical trials. Although treatment modalities are regularly assessed in mice upon tumor growth in vivo, surgical resection remains challenging, particularly in the orthotopic site. Here, we report a successful surgical resection of glioblastoma (GBM) in patient-derived orthotopic xenografts (PDOXs). Methods We derived a cohort of 46 GBM PDOX models that faithfully recapitulate human disease in mice. We assessed the detection and quantification of intracranial tumors using magnetic resonance imaging (MRI).To evaluate feasibility of surgical resection in PDOXs, we selected two models representing histopathological features of GBM tumors, including diffuse growth into the mouse brain. Surgical resection in the mouse brains was performed based on MRI-guided coordinates. Survival study followed by MRI and immunohistochemistry-based evaluation of recurrent tumors allowed for assessment of clinically relevant parameters. Results We demonstrate the utility of MRI for the noninvasive assessment of in vivo tumor growth, preoperative programming of resection coordinates and follow-up of tumor recurrence. We report tumor detection by MRI in 90% of GBM PDOX models (36/40), of which 55% (22/40) can be reliably quantified during tumor growth. We show that a surgical resection protocol in mice carrying diffuse primary GBM tumors in the brain leads to clinically relevant outcomes. Similar to neurosurgery in patients, we achieved a near total to complete extent of tumor resection, and mice with resected tumors presented significantly increased survival. The remaining unresected GBM cells that invaded the normal mouse brain prior to surgery regrew tumors with similar histopathological features and tumor microenvironments to the primary tumors. Conclusions Our data positions GBM PDOXs developed in mouse brains as a valuable preclinical model for conducting therapeutic studies that involve surgical tumor resection. The high detectability of tumors by MRI across a substantial number of PDOX models in mice will allow for scalability of our approach toward specific tumor types for efficacy studies in precision medicine-oriented approaches. Additionally, these models hold promise for the development of enhanced image-guided surgery protocols.
- Published
- 2024
- Full Text
- View/download PDF
6. Author Correction: Federated learning enables big data for rare cancer boundary detection
- Author
-
Pati, Sarthak, Baid, Ujjwal, Edwards, Brandon, Sheller, Micah, Wang, Shih-Han, Reina, G. Anthony, Foley, Patrick, Gruzdev, Alexey, Karkada, Deepthi, Davatzikos, Christos, Sako, Chiharu, Ghodasara, Satyam, Bilello, Michel, Mohan, Suyash, Vollmuth, Philipp, Brugnara, Gianluca, Preetha, Chandrakanth J., Sahm, Felix, Maier-Hein, Klaus, Zenk, Maximilian, Bendszus, Martin, Wick, Wolfgang, Calabrese, Evan, Rudie, Jeffrey, Villanueva-Meyer, Javier, Cha, Soonmee, Ingalhalikar, Madhura, Jadhav, Manali, Pandey, Umang, Saini, Jitender, Garrett, John, Larson, Matthew, Jeraj, Robert, Currie, Stuart, Frood, Russell, Fatania, Kavi, Huang, Raymond Y., Chang, Ken, Balaña, Carmen, Capellades, Jaume, Puig, Josep, Trenkler, Johannes, Pichler, Josef, Necker, Georg, Haunschmidt, Andreas, Meckel, Stephan, Shukla, Gaurav, Liem, Spencer, Alexander, Gregory S., Lombardo, Joseph, Palmer, Joshua D., Flanders, Adam E., Dicker, Adam P., Sair, Haris I., Jones, Craig K., Venkataraman, Archana, Jiang, Meirui, So, Tiffany Y., Chen, Cheng, Heng, Pheng Ann, Dou, Qi, Kozubek, Michal, Lux, Filip, Michálek, Jan, Matula, Petr, Keřkovský, Miloš, Kopřivová, Tereza, Dostál, Marek, Vybíhal, Václav, Vogelbaum, Michael A., Mitchell, J. Ross, Farinhas, Joaquim, Maldjian, Joseph A., Yogananda, Chandan Ganesh Bangalore, Pinho, Marco C., Reddy, Divya, Holcomb, James, Wagner, Benjamin C., Ellingson, Benjamin M., Cloughesy, Timothy F., Raymond, Catalina, Oughourlian, Talia, Hagiwara, Akifumi, Wang, Chencai, To, Minh-Son, Bhardwaj, Sargam, Chong, Chee, Agzarian, Marc, Falcão, Alexandre Xavier, Martins, Samuel B., Teixeira, Bernardo C. A., Sprenger, Flávia, Menotti, David, Lucio, Diego R., LaMontagne, Pamela, Marcus, Daniel, Wiestler, Benedikt, Kofler, Florian, Ezhov, Ivan, Metz, Marie, Jain, Rajan, Lee, Matthew, Lui, Yvonne W., McKinley, Richard, Slotboom, Johannes, Radojewski, Piotr, Meier, Raphael, Wiest, Roland, Murcia, Derrick, Fu, Eric, Haas, Rourke, Thompson, John, Ormond, David Ryan, Badve, Chaitra, Sloan, Andrew E., Vadmal, Vachan, Waite, Kristin, Colen, Rivka R., Pei, Linmin, Ak, Murat, Srinivasan, Ashok, Bapuraj, J. Rajiv, Rao, Arvind, Wang, Nicholas, Yoshiaki, Ota, Moritani, Toshio, Turk, Sevcan, Lee, Joonsang, Prabhudesai, Snehal, Morón, Fanny, Mandel, Jacob, Kamnitsas, Konstantinos, Glocker, Ben, Dixon, Luke V. M., Williams, Matthew, Zampakis, Peter, Panagiotopoulos, Vasileios, Tsiganos, Panagiotis, Alexiou, Sotiris, Haliassos, Ilias, Zacharaki, Evangelia I., Moustakas, Konstantinos, Kalogeropoulou, Christina, Kardamakis, Dimitrios M., Choi, Yoon Seong, Lee, Seung-Koo, Chang, Jong Hee, Ahn, Sung Soo, Luo, Bing, Poisson, Laila, Wen, Ning, Tiwari, Pallavi, Verma, Ruchika, Bareja, Rohan, Yadav, Ipsa, Chen, Jonathan, Kumar, Neeraj, Smits, Marion, van der Voort, Sebastian R., Alafandi, Ahmed, Incekara, Fatih, Wijnenga, Maarten M. J., Kapsas, Georgios, Gahrmann, Renske, Schouten, Joost W., Dubbink, Hendrikus J., Vincent, Arnaud J. P. E., van den Bent, Martin J., French, Pim J., Klein, Stefan, Yuan, Yading, Sharma, Sonam, Tseng, Tzu-Chi, Adabi, Saba, Niclou, Simone P., Keunen, Olivier, Hau, Ann-Christin, Vallières, Martin, Fortin, David, Lepage, Martin, Landman, Bennett, Ramadass, Karthik, Xu, Kaiwen, Chotai, Silky, Chambless, Lola B., Mistry, Akshitkumar, Thompson, Reid C., Gusev, Yuriy, Bhuvaneshwar, Krithika, Sayah, Anousheh, Bencheqroun, Camelia, Belouali, Anas, Madhavan, Subha, Booth, Thomas C., Chelliah, Alysha, Modat, Marc, Shuaib, Haris, Dragos, Carmen, Abayazeed, Aly, Kolodziej, Kenneth, Hill, Michael, Abbassy, Ahmed, Gamal, Shady, Mekhaimar, Mahmoud, Qayati, Mohamed, Reyes, Mauricio, Park, Ji Eun, Yun, Jihye, Kim, Ho Sung, Mahajan, Abhishek, Muzi, Mark, Benson, Sean, Beets-Tan, Regina G. H., Teuwen, Jonas, Herrera-Trujillo, Alejandro, Trujillo, Maria, Escobar, William, Abello, Ana, Bernal, Jose, Gómez, Jhon, Choi, Joseph, Baek, Stephen, Kim, Yusung, Ismael, Heba, Allen, Bryan, Buatti, John M., Kotrotsou, Aikaterini, Li, Hongwei, Weiss, Tobias, Weller, Michael, Bink, Andrea, Pouymayou, Bertrand, Shaykh, Hassan F., Saltz, Joel, Prasanna, Prateek, Shrestha, Sampurna, Mani, Kartik M., Payne, David, Kurc, Tahsin, Pelaez, Enrique, Franco-Maldonado, Heydy, Loayza, Francis, Quevedo, Sebastian, Guevara, Pamela, Torche, Esteban, Mendoza, Cristobal, Vera, Franco, Ríos, Elvis, López, Eduardo, Velastin, Sergio A., Ogbole, Godwin, Soneye, Mayowa, Oyekunle, Dotun, Odafe-Oyibotha, Olubunmi, Osobu, Babatunde, Shu’aibu, Mustapha, Dorcas, Adeleye, Dako, Farouk, Simpson, Amber L., Hamghalam, Mohammad, Peoples, Jacob J., Hu, Ricky, Tran, Anh, Cutler, Danielle, Moraes, Fabio Y., Boss, Michael A., Gimpel, James, Veettil, Deepak Kattil, Schmidt, Kendall, Bialecki, Brian, Marella, Sailaja, Price, Cynthia, Cimino, Lisa, Apgar, Charles, Shah, Prashant, Menze, Bjoern, Barnholtz-Sloan, Jill S., Martin, Jason, and Bakas, Spyridon
- Published
- 2023
- Full Text
- View/download PDF
7. PKM2 diverts glycolytic flux in dependence on mitochondrial one-carbon cycle
- Author
-
Mohaned Benzarti, Laura Neises, Anais Oudin, Christina Krötz, Elodie Viry, Ernesto Gargiulo, Coralie Pulido, Maryse Schmoetten, Vitaly Pozdeev, Nadia I. Lorenz, Michael W. Ronellenfitsch, David Sumpton, Marc Warmoes, Christian Jaeger, Antoine Lesur, Björn Becker, Etienne Moussay, Jerome Paggetti, Simone P. Niclou, Elisabeth Letellier, and Johannes Meiser
- Subjects
CP: Cancer ,CP: Metabolism ,Biology (General) ,QH301-705.5 - Abstract
Summary: Modeling tumor metabolism in vitro remains challenging. Here, we used galactose as an in vitro tool compound to mimic glycolytic limitation. In contrast to the established idea that high glycolytic flux reduces pyruvate kinase isozyme M2 (PKM2) activity to support anabolic processes, we have discovered that glycolytic limitation also affects PKM2 activity. Surprisingly, despite limited carbon availability and energetic stress, cells induce a near-complete block of PKM2 to divert carbons toward serine metabolism. Simultaneously, TCA cycle flux is sustained, and oxygen consumption is increased, supported by glutamine. Glutamine not only supports TCA cycle flux but also serine synthesis via distinct mechanisms that are directed through PKM2 inhibition. Finally, deleting mitochondrial one-carbon (1C) cycle reversed the PKM2 block, suggesting a potential formate-dependent crosstalk that coordinates mitochondrial 1C flux and cytosolic glycolysis to support cell survival and proliferation during nutrient-scarce conditions.
- Published
- 2024
- Full Text
- View/download PDF
8. PKM2 diverts glycolytic flux in dependence on mitochondrial one-carbon cycle
- Author
-
Benzarti, Mohaned, Neises, Laura, Oudin, Anais, Krötz, Christina, Viry, Elodie, Gargiulo, Ernesto, Pulido, Coralie, Schmoetten, Maryse, Pozdeev, Vitaly, Lorenz, Nadia I., Ronellenfitsch, Michael W., Sumpton, David, Warmoes, Marc, Jaeger, Christian, Lesur, Antoine, Becker, Björn, Moussay, Etienne, Paggetti, Jerome, Niclou, Simone P., Letellier, Elisabeth, and Meiser, Johannes
- Published
- 2024
- Full Text
- View/download PDF
9. Formate promotes invasion and metastasis in reliance on lipid metabolism
- Author
-
Catherine Delbrouck, Nicole Kiweler, Oleg Chen, Vitaly I. Pozdeev, Lara Haase, Laura Neises, Anaïs Oudin, Aymeric Fouquier d’Hérouël, Ruolin Shen, Lisa Schlicker, Rashi Halder, Antoine Lesur, Anne Schuster, Nadja I. Lorenz, Christian Jaeger, Maureen Feucherolles, Gilles Frache, Martyna Szpakowska, Andy Chevigne, Michael W. Ronellenfitsch, Etienne Moussay, Marie Piraud, Alexander Skupin, Almut Schulze, Simone P. Niclou, Elisabeth Letellier, and Johannes Meiser
- Subjects
CP: Cancer ,CP: Metabolism ,Biology (General) ,QH301-705.5 - Abstract
Summary: Metabolic rewiring is essential for cancer onset and progression. We previously showed that one-carbon metabolism-dependent formate production often exceeds the anabolic demand of cancer cells, resulting in formate overflow. Furthermore, we showed that increased extracellular formate concentrations promote the in vitro invasiveness of glioblastoma cells. Here, we substantiate these initial observations with ex vivo and in vivo experiments. We also show that exposure to exogeneous formate can prime cancer cells toward a pro-invasive phenotype leading to increased metastasis formation in vivo. Our results suggest that the increased local formate concentration within the tumor microenvironment can be one factor to promote metastases. Additionally, we describe a mechanistic interplay between formate-dependent increased invasiveness and adaptations of lipid metabolism and matrix metalloproteinase activity. Our findings consolidate the role of formate as pro-invasive metabolite and warrant further research to better understand the interplay between formate and lipid metabolism.
- Published
- 2023
- Full Text
- View/download PDF
10. Longitudinal molecular trajectories of diffuse glioma in adults
- Author
-
Barthel, Floris P, Johnson, Kevin C, Varn, Frederick S, Moskalik, Anzhela D, Tanner, Georgette, Kocakavuk, Emre, Anderson, Kevin J, Abiola, Olajide, Aldape, Kenneth, Alfaro, Kristin D, Alpar, Donat, Amin, Samirkumar B, Ashley, David M, Bandopadhayay, Pratiti, Barnholtz-Sloan, Jill S, Beroukhim, Rameen, Bock, Christoph, Brastianos, Priscilla K, Brat, Daniel J, Brodbelt, Andrew R, Bruns, Alexander F, Bulsara, Ketan R, Chakrabarty, Aruna, Chakravarti, Arnab, Chuang, Jeffrey H, Claus, Elizabeth B, Cochran, Elizabeth J, Connelly, Jennifer, Costello, Joseph F, Finocchiaro, Gaetano, Fletcher, Michael N, French, Pim J, Gan, Hui K, Gilbert, Mark R, Gould, Peter V, Grimmer, Matthew R, Iavarone, Antonio, Ismail, Azzam, Jenkinson, Michael D, Khasraw, Mustafa, Kim, Hoon, Kouwenhoven, Mathilde CM, LaViolette, Peter S, Li, Meihong, Lichter, Peter, Ligon, Keith L, Lowman, Allison K, Malta, Tathiane M, Mazor, Tali, McDonald, Kerrie L, Molinaro, Annette M, Nam, Do-Hyun, Nayyar, Naema, Ng, Ho Keung, Ngan, Chew Yee, Niclou, Simone P, Niers, Johanna M, Noushmehr, Houtan, Noorbakhsh, Javad, Ormond, D Ryan, Park, Chul-Kee, Poisson, Laila M, Rabadan, Raul, Radlwimmer, Bernhard, Rao, Ganesh, Reifenberger, Guido, Sa, Jason K, Schuster, Michael, Shaw, Brian L, Short, Susan C, Smitt, Peter A Sillevis, Sloan, Andrew E, Smits, Marion, Suzuki, Hiromichi, Tabatabai, Ghazaleh, Van Meir, Erwin G, Watts, Colin, Weller, Michael, Wesseling, Pieter, Westerman, Bart A, Widhalm, Georg, Woehrer, Adelheid, Yung, WK Alfred, Zadeh, Gelareh, Huse, Jason T, De Groot, John F, Stead, Lucy F, and Verhaak, Roel GW
- Subjects
Neurosciences ,Brain Disorders ,Cancer ,Rare Diseases ,Brain Cancer ,Genetics ,Adult ,Chromosomes ,Human ,Pair 1 ,Chromosomes ,Human ,Pair 19 ,Disease Progression ,Glioma ,Humans ,Isocitrate Dehydrogenase ,Mutation ,Polymorphism ,Single Nucleotide ,Recurrence ,GLASS Consortium ,General Science & Technology - Abstract
The evolutionary processes that drive universal therapeutic resistance in adult patients with diffuse glioma remain unclear1,2. Here we analysed temporally separated DNA-sequencing data and matched clinical annotation from 222 adult patients with glioma. By analysing mutations and copy numbers across the three major subtypes of diffuse glioma, we found that driver genes detected at the initial stage of disease were retained at recurrence, whereas there was little evidence of recurrence-specific gene alterations. Treatment with alkylating agents resulted in a hypermutator phenotype at different rates across the glioma subtypes, and hypermutation was not associated with differences in overall survival. Acquired aneuploidy was frequently detected in recurrent gliomas and was characterized by IDH mutation but without co-deletion of chromosome arms 1p/19q, and further converged with acquired alterations in the cell cycle and poor outcomes. The clonal architecture of each tumour remained similar over time, but the presence of subclonal selection was associated with decreased survival. Finally, there were no differences in the levels of immunoediting between initial and recurrent gliomas. Collectively, our results suggest that the strongest selective pressures occur during early glioma development and that current therapies shape this evolution in a largely stochastic manner.
- Published
- 2019
11. Federated learning enables big data for rare cancer boundary detection
- Author
-
Sarthak Pati, Ujjwal Baid, Brandon Edwards, Micah Sheller, Shih-Han Wang, G. Anthony Reina, Patrick Foley, Alexey Gruzdev, Deepthi Karkada, Christos Davatzikos, Chiharu Sako, Satyam Ghodasara, Michel Bilello, Suyash Mohan, Philipp Vollmuth, Gianluca Brugnara, Chandrakanth J. Preetha, Felix Sahm, Klaus Maier-Hein, Maximilian Zenk, Martin Bendszus, Wolfgang Wick, Evan Calabrese, Jeffrey Rudie, Javier Villanueva-Meyer, Soonmee Cha, Madhura Ingalhalikar, Manali Jadhav, Umang Pandey, Jitender Saini, John Garrett, Matthew Larson, Robert Jeraj, Stuart Currie, Russell Frood, Kavi Fatania, Raymond Y. Huang, Ken Chang, Carmen Balaña Quintero, Jaume Capellades, Josep Puig, Johannes Trenkler, Josef Pichler, Georg Necker, Andreas Haunschmidt, Stephan Meckel, Gaurav Shukla, Spencer Liem, Gregory S. Alexander, Joseph Lombardo, Joshua D. Palmer, Adam E. Flanders, Adam P. Dicker, Haris I. Sair, Craig K. Jones, Archana Venkataraman, Meirui Jiang, Tiffany Y. So, Cheng Chen, Pheng Ann Heng, Qi Dou, Michal Kozubek, Filip Lux, Jan Michálek, Petr Matula, Miloš Keřkovský, Tereza Kopřivová, Marek Dostál, Václav Vybíhal, Michael A. Vogelbaum, J. Ross Mitchell, Joaquim Farinhas, Joseph A. Maldjian, Chandan Ganesh Bangalore Yogananda, Marco C. Pinho, Divya Reddy, James Holcomb, Benjamin C. Wagner, Benjamin M. Ellingson, Timothy F. Cloughesy, Catalina Raymond, Talia Oughourlian, Akifumi Hagiwara, Chencai Wang, Minh-Son To, Sargam Bhardwaj, Chee Chong, Marc Agzarian, Alexandre Xavier Falcão, Samuel B. Martins, Bernardo C. A. Teixeira, Flávia Sprenger, David Menotti, Diego R. Lucio, Pamela LaMontagne, Daniel Marcus, Benedikt Wiestler, Florian Kofler, Ivan Ezhov, Marie Metz, Rajan Jain, Matthew Lee, Yvonne W. Lui, Richard McKinley, Johannes Slotboom, Piotr Radojewski, Raphael Meier, Roland Wiest, Derrick Murcia, Eric Fu, Rourke Haas, John Thompson, David Ryan Ormond, Chaitra Badve, Andrew E. Sloan, Vachan Vadmal, Kristin Waite, Rivka R. Colen, Linmin Pei, Murat Ak, Ashok Srinivasan, J. Rajiv Bapuraj, Arvind Rao, Nicholas Wang, Ota Yoshiaki, Toshio Moritani, Sevcan Turk, Joonsang Lee, Snehal Prabhudesai, Fanny Morón, Jacob Mandel, Konstantinos Kamnitsas, Ben Glocker, Luke V. M. Dixon, Matthew Williams, Peter Zampakis, Vasileios Panagiotopoulos, Panagiotis Tsiganos, Sotiris Alexiou, Ilias Haliassos, Evangelia I. Zacharaki, Konstantinos Moustakas, Christina Kalogeropoulou, Dimitrios M. Kardamakis, Yoon Seong Choi, Seung-Koo Lee, Jong Hee Chang, Sung Soo Ahn, Bing Luo, Laila Poisson, Ning Wen, Pallavi Tiwari, Ruchika Verma, Rohan Bareja, Ipsa Yadav, Jonathan Chen, Neeraj Kumar, Marion Smits, Sebastian R. van der Voort, Ahmed Alafandi, Fatih Incekara, Maarten M. J. Wijnenga, Georgios Kapsas, Renske Gahrmann, Joost W. Schouten, Hendrikus J. Dubbink, Arnaud J. P. E. Vincent, Martin J. van den Bent, Pim J. French, Stefan Klein, Yading Yuan, Sonam Sharma, Tzu-Chi Tseng, Saba Adabi, Simone P. Niclou, Olivier Keunen, Ann-Christin Hau, Martin Vallières, David Fortin, Martin Lepage, Bennett Landman, Karthik Ramadass, Kaiwen Xu, Silky Chotai, Lola B. Chambless, Akshitkumar Mistry, Reid C. Thompson, Yuriy Gusev, Krithika Bhuvaneshwar, Anousheh Sayah, Camelia Bencheqroun, Anas Belouali, Subha Madhavan, Thomas C. Booth, Alysha Chelliah, Marc Modat, Haris Shuaib, Carmen Dragos, Aly Abayazeed, Kenneth Kolodziej, Michael Hill, Ahmed Abbassy, Shady Gamal, Mahmoud Mekhaimar, Mohamed Qayati, Mauricio Reyes, Ji Eun Park, Jihye Yun, Ho Sung Kim, Abhishek Mahajan, Mark Muzi, Sean Benson, Regina G. H. Beets-Tan, Jonas Teuwen, Alejandro Herrera-Trujillo, Maria Trujillo, William Escobar, Ana Abello, Jose Bernal, Jhon Gómez, Joseph Choi, Stephen Baek, Yusung Kim, Heba Ismael, Bryan Allen, John M. Buatti, Aikaterini Kotrotsou, Hongwei Li, Tobias Weiss, Michael Weller, Andrea Bink, Bertrand Pouymayou, Hassan F. Shaykh, Joel Saltz, Prateek Prasanna, Sampurna Shrestha, Kartik M. Mani, David Payne, Tahsin Kurc, Enrique Pelaez, Heydy Franco-Maldonado, Francis Loayza, Sebastian Quevedo, Pamela Guevara, Esteban Torche, Cristobal Mendoza, Franco Vera, Elvis Ríos, Eduardo López, Sergio A. Velastin, Godwin Ogbole, Mayowa Soneye, Dotun Oyekunle, Olubunmi Odafe-Oyibotha, Babatunde Osobu, Mustapha Shu’aibu, Adeleye Dorcas, Farouk Dako, Amber L. Simpson, Mohammad Hamghalam, Jacob J. Peoples, Ricky Hu, Anh Tran, Danielle Cutler, Fabio Y. Moraes, Michael A. Boss, James Gimpel, Deepak Kattil Veettil, Kendall Schmidt, Brian Bialecki, Sailaja Marella, Cynthia Price, Lisa Cimino, Charles Apgar, Prashant Shah, Bjoern Menze, Jill S. Barnholtz-Sloan, Jason Martin, and Spyridon Bakas
- Subjects
Science - Abstract
Federated ML (FL) provides an alternative to train accurate and generalizable ML models, by only sharing numerical model updates. Here, the authors present the largest FL study to-date to generate an automatic tumor boundary detector for glioblastoma.
- Published
- 2022
- Full Text
- View/download PDF
12. Elucidating tumour‐associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency
- Author
-
Yolanda Pires‐Afonso, Arnaud Muller, Kamil Grzyb, Anaïs Oudin, Yahaya A. Yabo, Carole Sousa, Andrea Scafidi, Aurélie Poli, Antonio Cosma, Rashi Halder, Djalil Coowar, Anna Golebiewska, Alexander Skupin, Simone P. Niclou, and Alessandro Michelucci
- Subjects
ACOD1/IRG1 ,glioblastoma ,heterogeneity ,metabolic reprogramming ,single‐cell RNA‐sequencing ,tumour‐associated microglia/macrophages ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
In glioblastoma (GBM), tumour‐associated microglia/macrophages (TAMs) represent the major cell type of the stromal compartment and contribute to tumour immune escape mechanisms. Thus, targeting TAMs is emerging as a promising strategy for immunotherapy. However, TAM heterogeneity and metabolic adaptation along GBM progression represent critical features for the design of effective TAM‐targeted therapies. Here, we comprehensively study the cellular and molecular changes of TAMs in the GL261 GBM mouse model, combining single‐cell RNA‐sequencing with flow cytometry and immunohistological analyses along GBM progression and in the absence of Acod1 (also known as Irg1), a key gene involved in the metabolic reprogramming of macrophages towards an anti‐inflammatory phenotype. Similarly to patients, we identify distinct TAM profiles, mainly based on their ontogeny, that reiterate the idea that microglia‐ and macrophage‐like cells show key transcriptional differences and dynamically adapt along GBM stages. Notably, we uncover decreased antigen‐presenting cell features and immune reactivity in TAMs along tumour progression that are instead enhanced in Acod1‐deficient mice. Overall, our results provide insight into TAM heterogeneity and highlight a novel role for Acod1 in TAM adaptation during GBM progression.
- Published
- 2022
- Full Text
- View/download PDF
13. Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas
- Author
-
Nesseler, Jean Philippe, Schaue, Dorthe, McBride, William H, Lee, Mi-Heon, Kaprealian, Tania, Niclou, Simone P, and Nickers, Philippe
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Vaccine Related ,Neurosciences ,Immunization ,Brain Cancer ,Rare Diseases ,Cancer ,Brain Disorders ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Oncology and carcinogenesis - Abstract
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for immunotherapy. However, GBM tends to be nonimmunogenic and exhibits a microenvironment with few or no effector T cells, a relatively low nonsynonymous somatic mutational load, and a low predicted neoantigen burden. GBM also exploits a multitude of immunosuppressive strategies.Methods and materialsA number of immunotherapeutic approaches have been tested with disappointing results. A rationale exists to combine immunotherapy and radiation therapy, which can induce an immunogenic form of cell death with T-cell activation and tumor infiltration.ResultsVarious immunotherapy agents, including immune checkpoint modulators, transforming growth factor beta receptor inhibitors, and indoleamine-2,3-dioxygenase inhibitors, have been evaluated with irradiation in preclinical GBM models, with promising results, and are being further tested in clinical trials.ConclusionsThis review aims to present the basic rationale behind this emerging complementary therapeutic approach in GBM, appraise the current preclinical and clinical data, and discuss the future challenges in improving the antitumor immune response.
- Published
- 2019
14. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium
- Author
-
Aldape, Kenneth, Amin, Samirkumar B, Ashley, David M, Barnholtz-Sloan, Jill S, Bates, Amanda J, Beroukhim, Rameen, Bock, Christoph, Brat, Daniel J, Claus, Elizabeth B, Costello, Joseph F, de Groot, John F, Finocchiaro, Gaetano, French, Pim J, Gan, Hui K, Griffith, Brent, Herold-Mende, Christel C, Horbinski, Craig, Iavarone, Antonio, Kalkanis, Steven N, Karabatsou, Konstantina, Kim, Hoon, Kouwenhoven, Mathilde CM, McDonald, Kerrie L, Miletic, Hrvoje, Nam, Do-Hyun, Ng, Ho Keung, Niclou, Simone P, Noushmehr, Houtan, Ormond, D Ryan, Poisson, Laila M, Reifenberger, Guido, Roncaroli, Federico, Sa, Jason K, Smitt, Peter AE Sillevis, Smits, Marion, Souza, Camila F, Tabatabai, Ghazaleh, Van Meir, Erwin G, Verhaak, Roel GW, Watts, Colin, Wesseling, Pieter, Woehrer, Adelheid, Yung, WK Alfred, Jungk, Christine, Hau, Ann-Christin, van Dyck, Eric, Westerman, Bart A, Yin, Julia, Abiola, Olajide, Zeps, Nikolaj, Grimmond, Sean, Buckland, Michael, Khasraw, Mustafa, Sulman, Erik P, Muscat, Andrea M, and Stead, Lucy
- Subjects
Cancer ,Human Genome ,Brain Cancer ,Rare Diseases ,Orphan Drug ,Brain Disorders ,Neurosciences ,Genetics ,Brain Neoplasms ,Evolution ,Molecular ,Genomics ,Glioma ,Humans ,Longitudinal Studies ,characterization ,evolution ,glioma ,sequencing ,subtypes ,GLASS Consortium ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their families. The Cancer Genome Atlas and similar projects have provided a comprehensive understanding of the somatic alterations and molecular subtypes of glioma at diagnosis. However, gliomas undergo significant cellular and molecular evolution during disease progression. We review the current knowledge on the genomic and epigenetic abnormalities in primary tumors and after disease recurrence, highlight the gaps in the literature, and elaborate on the need for a new multi-institutional effort to bridge these knowledge gaps and how the Glioma Longitudinal Analysis Consortium (GLASS) aims to systemically catalog the longitudinal changes in gliomas. The GLASS initiative will provide essential insights into the evolution of glioma toward a lethal phenotype, with the potential to reveal targetable vulnerabilities and, ultimately, improved outcomes for a patient population in need.
- Published
- 2018
15. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry
- Author
-
Amit Kulkarni, Tiago Ferreira, Clemens Bretscher, Annabel Grewenig, Nazim El-Andaloussi, Serena Bonifati, Tiina Marttila, Valérie Palissot, Jubayer A. Hossain, Francisco Azuaje, Hrvoje Miletic, Lars A. R. Ystaas, Anna Golebiewska, Simone P. Niclou, Ralf Roeth, Beate Niesler, Amélie Weiss, Laurent Brino, and Antonio Marchini
- Subjects
Science - Abstract
Rat H-1 parvovirus (H-1PV) is in clinical development for oncolytic therapy. Here, Kulkarni et al. identify LAMC1 as a modulator of H-1PV cell attachment and entry and find that LAMC1 levels and H-1PV oncolytic activity correlate in 59 tested cancer cell lines.
- Published
- 2021
- Full Text
- View/download PDF
16. Author Correction: Federated learning enables big data for rare cancer boundary detection
- Author
-
Sarthak Pati, Ujjwal Baid, Brandon Edwards, Micah Sheller, Shih-Han Wang, G. Anthony Reina, Patrick Foley, Alexey Gruzdev, Deepthi Karkada, Christos Davatzikos, Chiharu Sako, Satyam Ghodasara, Michel Bilello, Suyash Mohan, Philipp Vollmuth, Gianluca Brugnara, Chandrakanth J. Preetha, Felix Sahm, Klaus Maier-Hein, Maximilian Zenk, Martin Bendszus, Wolfgang Wick, Evan Calabrese, Jeffrey Rudie, Javier Villanueva-Meyer, Soonmee Cha, Madhura Ingalhalikar, Manali Jadhav, Umang Pandey, Jitender Saini, John Garrett, Matthew Larson, Robert Jeraj, Stuart Currie, Russell Frood, Kavi Fatania, Raymond Y. Huang, Ken Chang, Carmen Balaña, Jaume Capellades, Josep Puig, Johannes Trenkler, Josef Pichler, Georg Necker, Andreas Haunschmidt, Stephan Meckel, Gaurav Shukla, Spencer Liem, Gregory S. Alexander, Joseph Lombardo, Joshua D. Palmer, Adam E. Flanders, Adam P. Dicker, Haris I. Sair, Craig K. Jones, Archana Venkataraman, Meirui Jiang, Tiffany Y. So, Cheng Chen, Pheng Ann Heng, Qi Dou, Michal Kozubek, Filip Lux, Jan Michálek, Petr Matula, Miloš Keřkovský, Tereza Kopřivová, Marek Dostál, Václav Vybíhal, Michael A. Vogelbaum, J. Ross Mitchell, Joaquim Farinhas, Joseph A. Maldjian, Chandan Ganesh Bangalore Yogananda, Marco C. Pinho, Divya Reddy, James Holcomb, Benjamin C. Wagner, Benjamin M. Ellingson, Timothy F. Cloughesy, Catalina Raymond, Talia Oughourlian, Akifumi Hagiwara, Chencai Wang, Minh-Son To, Sargam Bhardwaj, Chee Chong, Marc Agzarian, Alexandre Xavier Falcão, Samuel B. Martins, Bernardo C. A. Teixeira, Flávia Sprenger, David Menotti, Diego R. Lucio, Pamela LaMontagne, Daniel Marcus, Benedikt Wiestler, Florian Kofler, Ivan Ezhov, Marie Metz, Rajan Jain, Matthew Lee, Yvonne W. Lui, Richard McKinley, Johannes Slotboom, Piotr Radojewski, Raphael Meier, Roland Wiest, Derrick Murcia, Eric Fu, Rourke Haas, John Thompson, David Ryan Ormond, Chaitra Badve, Andrew E. Sloan, Vachan Vadmal, Kristin Waite, Rivka R. Colen, Linmin Pei, Murat Ak, Ashok Srinivasan, J. Rajiv Bapuraj, Arvind Rao, Nicholas Wang, Ota Yoshiaki, Toshio Moritani, Sevcan Turk, Joonsang Lee, Snehal Prabhudesai, Fanny Morón, Jacob Mandel, Konstantinos Kamnitsas, Ben Glocker, Luke V. M. Dixon, Matthew Williams, Peter Zampakis, Vasileios Panagiotopoulos, Panagiotis Tsiganos, Sotiris Alexiou, Ilias Haliassos, Evangelia I. Zacharaki, Konstantinos Moustakas, Christina Kalogeropoulou, Dimitrios M. Kardamakis, Yoon Seong Choi, Seung-Koo Lee, Jong Hee Chang, Sung Soo Ahn, Bing Luo, Laila Poisson, Ning Wen, Pallavi Tiwari, Ruchika Verma, Rohan Bareja, Ipsa Yadav, Jonathan Chen, Neeraj Kumar, Marion Smits, Sebastian R. van der Voort, Ahmed Alafandi, Fatih Incekara, Maarten M. J. Wijnenga, Georgios Kapsas, Renske Gahrmann, Joost W. Schouten, Hendrikus J. Dubbink, Arnaud J. P. E. Vincent, Martin J. van den Bent, Pim J. French, Stefan Klein, Yading Yuan, Sonam Sharma, Tzu-Chi Tseng, Saba Adabi, Simone P. Niclou, Olivier Keunen, Ann-Christin Hau, Martin Vallières, David Fortin, Martin Lepage, Bennett Landman, Karthik Ramadass, Kaiwen Xu, Silky Chotai, Lola B. Chambless, Akshitkumar Mistry, Reid C. Thompson, Yuriy Gusev, Krithika Bhuvaneshwar, Anousheh Sayah, Camelia Bencheqroun, Anas Belouali, Subha Madhavan, Thomas C. Booth, Alysha Chelliah, Marc Modat, Haris Shuaib, Carmen Dragos, Aly Abayazeed, Kenneth Kolodziej, Michael Hill, Ahmed Abbassy, Shady Gamal, Mahmoud Mekhaimar, Mohamed Qayati, Mauricio Reyes, Ji Eun Park, Jihye Yun, Ho Sung Kim, Abhishek Mahajan, Mark Muzi, Sean Benson, Regina G. H. Beets-Tan, Jonas Teuwen, Alejandro Herrera-Trujillo, Maria Trujillo, William Escobar, Ana Abello, Jose Bernal, Jhon Gómez, Joseph Choi, Stephen Baek, Yusung Kim, Heba Ismael, Bryan Allen, John M. Buatti, Aikaterini Kotrotsou, Hongwei Li, Tobias Weiss, Michael Weller, Andrea Bink, Bertrand Pouymayou, Hassan F. Shaykh, Joel Saltz, Prateek Prasanna, Sampurna Shrestha, Kartik M. Mani, David Payne, Tahsin Kurc, Enrique Pelaez, Heydy Franco-Maldonado, Francis Loayza, Sebastian Quevedo, Pamela Guevara, Esteban Torche, Cristobal Mendoza, Franco Vera, Elvis Ríos, Eduardo López, Sergio A. Velastin, Godwin Ogbole, Mayowa Soneye, Dotun Oyekunle, Olubunmi Odafe-Oyibotha, Babatunde Osobu, Mustapha Shu’aibu, Adeleye Dorcas, Farouk Dako, Amber L. Simpson, Mohammad Hamghalam, Jacob J. Peoples, Ricky Hu, Anh Tran, Danielle Cutler, Fabio Y. Moraes, Michael A. Boss, James Gimpel, Deepak Kattil Veettil, Kendall Schmidt, Brian Bialecki, Sailaja Marella, Cynthia Price, Lisa Cimino, Charles Apgar, Prashant Shah, Bjoern Menze, Jill S. Barnholtz-Sloan, Jason Martin, and Spyridon Bakas
- Subjects
Science - Published
- 2023
- Full Text
- View/download PDF
17. The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen
- Author
-
Malta, Tathiane M; https://orcid.org/0000-0003-1129-5791, Sabedot, Thais S; https://orcid.org/0000-0002-7813-483X, Morosini, Natalia S; https://orcid.org/0000-0002-9294-9461, Datta, Indrani; https://orcid.org/0000-0001-7548-9881, Garofano, Luciano; https://orcid.org/0000-0001-8582-0865, Vallentgoed, Wies R; https://orcid.org/0000-0001-6373-7710, Varn, Frederick S; https://orcid.org/0000-0001-6307-016X, Aldape, Kenneth; https://orcid.org/0000-0001-5119-7550, D'Angelo, Fulvio; https://orcid.org/0000-0002-4940-4693, Bakas, Spyridon; https://orcid.org/0000-0001-8734-6482, Barnholtz-Sloan, Jill S; https://orcid.org/0000-0001-6190-9304, Gan, Hui K; https://orcid.org/0000-0001-7319-8546, Hasanain, Mohammad; https://orcid.org/0000-0001-5207-101X, Hau, Ann-Christin; https://orcid.org/0000-0002-4412-2355, Johnson, Kevin C; https://orcid.org/0000-0003-0016-5158, Cazacu, Simona; https://orcid.org/0000-0002-6085-4177, deCarvalho, Ana C; https://orcid.org/0000-0003-1183-4548, Khasraw, Mustafa; https://orcid.org/0000-0003-3249-9849, Kocakavuk, Emre; https://orcid.org/0000-0003-1920-0494, Kouwenhoven, Mathilde C M; https://orcid.org/0000-0001-5252-4365, Migliozzi, Simona; https://orcid.org/0000-0002-4870-8943, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Niers, Johanna M; https://orcid.org/0000-0002-0366-8247, Ormond, D Ryan; https://orcid.org/0000-0001-7027-2915, Paek, Sun Ha; https://orcid.org/0000-0003-3007-8653, Reifenberger, Guido; https://orcid.org/0000-0002-1419-9837, Sillevis Smitt, Peter A; https://orcid.org/0000-0001-8044-6798, Smits, Marion; https://orcid.org/0000-0001-5563-2871, Weiss, Tobias; https://orcid.org/0000-0002-5533-9429, Weller, Michael; https://orcid.org/0000-0002-1748-174X, et al, Malta, Tathiane M; https://orcid.org/0000-0003-1129-5791, Sabedot, Thais S; https://orcid.org/0000-0002-7813-483X, Morosini, Natalia S; https://orcid.org/0000-0002-9294-9461, Datta, Indrani; https://orcid.org/0000-0001-7548-9881, Garofano, Luciano; https://orcid.org/0000-0001-8582-0865, Vallentgoed, Wies R; https://orcid.org/0000-0001-6373-7710, Varn, Frederick S; https://orcid.org/0000-0001-6307-016X, Aldape, Kenneth; https://orcid.org/0000-0001-5119-7550, D'Angelo, Fulvio; https://orcid.org/0000-0002-4940-4693, Bakas, Spyridon; https://orcid.org/0000-0001-8734-6482, Barnholtz-Sloan, Jill S; https://orcid.org/0000-0001-6190-9304, Gan, Hui K; https://orcid.org/0000-0001-7319-8546, Hasanain, Mohammad; https://orcid.org/0000-0001-5207-101X, Hau, Ann-Christin; https://orcid.org/0000-0002-4412-2355, Johnson, Kevin C; https://orcid.org/0000-0003-0016-5158, Cazacu, Simona; https://orcid.org/0000-0002-6085-4177, deCarvalho, Ana C; https://orcid.org/0000-0003-1183-4548, Khasraw, Mustafa; https://orcid.org/0000-0003-3249-9849, Kocakavuk, Emre; https://orcid.org/0000-0003-1920-0494, Kouwenhoven, Mathilde C M; https://orcid.org/0000-0001-5252-4365, Migliozzi, Simona; https://orcid.org/0000-0002-4870-8943, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Niers, Johanna M; https://orcid.org/0000-0002-0366-8247, Ormond, D Ryan; https://orcid.org/0000-0001-7027-2915, Paek, Sun Ha; https://orcid.org/0000-0003-3007-8653, Reifenberger, Guido; https://orcid.org/0000-0002-1419-9837, Sillevis Smitt, Peter A; https://orcid.org/0000-0001-8044-6798, Smits, Marion; https://orcid.org/0000-0001-5563-2871, Weiss, Tobias; https://orcid.org/0000-0002-5533-9429, Weller, Michael; https://orcid.org/0000-0002-1748-174X, and et al
- Abstract
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors. Integration of epigenomics, gene expression, and functional genomics identified HOXD13 as a master regulator of IDHmut astrocytoma evolution. Furthermore, relapse of IDHmut tumors was accompanied by histological progression that was associated with survival, as validated in an independent cohort. Finally, the initial cell composition of the tumor microenvironment varied between IDHwt and IDHmut tumors and changed differentially following treatment, suggesting increased neo-angiogenesis and T-cell infiltration upon treatment of IDHmut gliomas. This study provides one of the largest cohorts of paired longitudinal glioma samples with epigenomic, transcriptomic, and genomic profiling and suggests that treatment of IDHmut glioma is associated with epigenomic evolution towards an IDHwt-like phenotype.
- Published
- 2024
18. Gender balance and suitable positive actions to promote gender equality among healthcare professionals in neuro-oncology: The EANO positive action initiative
- Author
-
Le Rhun, Emilie; https://orcid.org/0000-0002-9408-3278, Boele, Florien; https://orcid.org/0000-0003-0409-7949, Minniti, Giuseppe; https://orcid.org/0000-0003-1239-1603, Galldiks, Norbert; https://orcid.org/0000-0002-2485-1796, Taphoorn, Martin; https://orcid.org/0000-0001-9949-4722, Piil, Karin; https://orcid.org/0000-0001-7972-4674, Rudà, Roberta, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Geurts, Marjolein; https://orcid.org/0000-0003-2369-0035, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Short, Susan C, Dirven, Linda; https://orcid.org/0000-0001-9157-9895, Le Rhun, Emilie; https://orcid.org/0000-0002-9408-3278, Boele, Florien; https://orcid.org/0000-0003-0409-7949, Minniti, Giuseppe; https://orcid.org/0000-0003-1239-1603, Galldiks, Norbert; https://orcid.org/0000-0002-2485-1796, Taphoorn, Martin; https://orcid.org/0000-0001-9949-4722, Piil, Karin; https://orcid.org/0000-0001-7972-4674, Rudà, Roberta, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Geurts, Marjolein; https://orcid.org/0000-0003-2369-0035, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Short, Susan C, and Dirven, Linda; https://orcid.org/0000-0001-9157-9895
- Abstract
Background The proportion of women among healthcare and biomedical research professionals in neuro-oncology is growing. With changes in cultural expectations and work-life balance considerations, more men aspire to nonfull-time jobs, yet, leadership positions remain dominated by men. Methods The European Association of Neuro-Oncology (EANO) disparity committee carried out a digital survey to explore gender balance and actions suitable to promote gender equality. The survey was distributed among EANO members in 2021, with responses analyzed descriptively. Results In total, 262 participants completed the survey (141 women, 53.8%; median age 43). Respondents were neurosurgeons (68, 26.0%); neurologists (67, 25.6%), medical oncologists (43, 16.4%), or other healthcare or research professionals; 208 participants (79.4%) worked full-time. Positive action to enforce the role of women in neuro-oncology was deemed necessary by 180 participants (68.7%), but only 28 participants (10.7%) agreed that women only should be promoted until gender balance is reached. A majority of respondents (162, 61.8%) felt that women with an equivalent CV should be prioritized over men to reach gender balance. If in the future the balance favored women at higher positions, 112 respondents (42.7%) agreed to apply positive action for men. The top indicators considered relevant to measure gender balance were: salary for similar positions (183/228, 80.3%), paid overtime (176/228, 77.2%), number of permanent positions (164/228, 71.9%), protected time for research (161/227, 70.9%), and training opportunities (157/227, 69.2%). Conclusions Specific indicators may help to measure and promote gender balance and should be considered for implementation among healthcare professionals in neuro-oncology.
- Published
- 2024
19. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen
- Author
-
Malta, Tathiane M., Sabedot, Thais S., Morosini, Natalia S., Datta, Indrani, Garofano, Luciano, Vallentgoed, Wies, Varn, Frederick S., Aldape, Kenneth, D'Angelo, Fulvio, Bakas, Spyridon, Barnholtz-Sloan, Jill S., Gan, Hui K., Hasanain, Mohammad, Hau, Ann Christin, Johnson, Kevin C., Cazacu, Simona, deCarvalho, Ana C., Khasraw, Mustafa, Kocakavuk, Emre, Kouwenhoven, Mathilde C.M., Migliozzi, Simona, Niclou, Simone P., Niers, Johanna M., Ormond, D. Ryan, Paek, Sun Ha, Reifenberger, Guido, Smitt, Peter A.Sillevis, Smits, Marion, Stead, Lucy F., van den Bent, Martin J., Van Meir, Erwin G., Walenkamp, Annemiek, Weiss, Tobias, Weller, Michael, Westerman, Bart A., Ylstra, Bauke, Wesseling, Pieter, Lasorella, Anna, French, Pim J., Poisson, Laila M., Verhaak, Roel G.W., Iavarone, Antonio, Noushmehr, Houtan, Malta, Tathiane M., Sabedot, Thais S., Morosini, Natalia S., Datta, Indrani, Garofano, Luciano, Vallentgoed, Wies, Varn, Frederick S., Aldape, Kenneth, D'Angelo, Fulvio, Bakas, Spyridon, Barnholtz-Sloan, Jill S., Gan, Hui K., Hasanain, Mohammad, Hau, Ann Christin, Johnson, Kevin C., Cazacu, Simona, deCarvalho, Ana C., Khasraw, Mustafa, Kocakavuk, Emre, Kouwenhoven, Mathilde C.M., Migliozzi, Simona, Niclou, Simone P., Niers, Johanna M., Ormond, D. Ryan, Paek, Sun Ha, Reifenberger, Guido, Smitt, Peter A.Sillevis, Smits, Marion, Stead, Lucy F., van den Bent, Martin J., Van Meir, Erwin G., Walenkamp, Annemiek, Weiss, Tobias, Weller, Michael, Westerman, Bart A., Ylstra, Bauke, Wesseling, Pieter, Lasorella, Anna, French, Pim J., Poisson, Laila M., Verhaak, Roel G.W., Iavarone, Antonio, and Noushmehr, Houtan
- Abstract
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors. Integration of epigenomics, gene expression, and functional genomics identified HOXD13 as a master regulator of IDHmut astrocytoma evolution. Furthermore, relapse of IDHmut tumors was accompanied by histologic progression that was associated with survival, as validated in an independent cohort. Finally, the initial cell composition of the tumor microenvironment varied between IDHwt and IDHmut tumors and changed differentially following treatment, suggesting increased neoangiogenesis and T-cell infiltration upon treatment of IDHmut gliomas. This study provides one of the largest cohorts of paired longitudinal glioma samples with epigenomic, transcriptomic, and genomic profiling and suggests that treatment of IDHmut glioma is associated with epigenomic evolution toward an IDHwt-like phenotype.
- Published
- 2024
20. AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion
- Author
-
Anne Schuster, Eliane Klein, Virginie Neirinckx, Arnon Møldrup Knudsen, Carina Fabian, Ann-Christin Hau, Monika Dieterle, Anais Oudin, Petr V. Nazarov, Anna Golebiewska, Arnaud Muller, Daniel Perez-Hernandez, Sophie Rodius, Gunnar Dittmar, Rolf Bjerkvig, Christel Herold-Mende, Barbara Klink, Bjarne Winther Kristensen, and Simone P. Niclou
- Subjects
Science - Abstract
Glioblastomas (GBMs) are highly invasive brain tumours, but the underlying mechanisms of GBM invasion are unclear. Here, the authors perform an RNA interference screen and identify AN1-Type Zinc Finger protein 3 (ZFAND3) as a regulator of GBM invasion, and find that it acts through the transcriptional regulation of invasion-related genes.
- Published
- 2020
- Full Text
- View/download PDF
21. Enzymatic activity of glycosyltransferase GLT8D1 promotes human glioblastoma cell migration
- Author
-
Elena I. Ilina, Camille Cialini, Dietlind L. Gerloff, Maitane Duarte Garcia-Escudero, Céline Jeanty, Marie-Laëtitia Thézénas, Antoine Lesur, Vincent Puard, François Bernardin, Alina Moter, Anne Schuster, Monika Dieterle, Anna Golebiewska, Jean-Jacques Gérardy, Gunnar Dittmar, Simone P. Niclou, Tanja Müller, and Michel Mittelbronn
- Subjects
Biochemistry ,Glycobiology ,Cell biology ,Cancer ,Science - Abstract
Summary: Glioblastoma (GBM) is the most aggressive primary brain tumor characterized by infiltrative growth of malignant glioma cells into the surrounding brain parenchyma. In this study, our analysis of GBM patient cohorts revealed a significantly higher expression of Glycosyltransferase 8 domain containing 1 (GLT8D1) compared to normal brain tissue and could be associated with impaired patient survival. Increased in vitro expression of GLT8D1 significantly enhanced migration of two different sphere-forming GBM cell lines. By in silico analysis we predicted the 3D-structure as well as the active site residues of GLT8D1. The introduction of point mutations in the predicted active site reduced its glycosyltransferase activity in vitro and consequently impaired GBM tumor cell migration. Examination of GLT8D1 interaction partners by LC-MS/MS implied proteins associated with cytoskeleton and intracellular transport as potential substrates. In conclusion, we demonstrated that the enzymatic activity of glycosyltransferase GLT8D1 promotes GBM cell migration.
- Published
- 2022
- Full Text
- View/download PDF
22. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry
- Author
-
Kulkarni, Amit, Ferreira, Tiago, Bretscher, Clemens, Grewenig, Annabel, El-Andaloussi, Nazim, Bonifati, Serena, Marttila, Tiina, Palissot, Valérie, Hossain, Jubayer A., Azuaje, Francisco, Miletic, Hrvoje, Ystaas, Lars A. R., Golebiewska, Anna, Niclou, Simone P., Roeth, Ralf, Niesler, Beate, Weiss, Amélie, Brino, Laurent, and Marchini, Antonio
- Published
- 2021
- Full Text
- View/download PDF
23. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
- Author
-
David Capper, Guido Reifenberger, Pim J French, Leonille Schweizer, Michael Weller, Mehdi Touat, Simone P Niclou, Philipp Euskirchen, Christine Haberler, Monika E Hegi, Sebastian Brandner, Emilie Le Rhun, Roberta Rudà, Marc Sanson, Ghazaleh Tabatabai, Felix Sahm, Patrick Y Wen, Pieter Wesseling, Matthias Preusser, Martin J van den Bent, Neurology, Pathology, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Imaging and biomarkers
- Subjects
Cancer Research ,Oncology ,SDG 3 - Good Health and Well-being ,Neurology (clinical) - Abstract
The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied. Despite that, there is increasing use of advanced molecular diagnostics that identify potential targets, and tumor-agnostic regulatory approvals on targets also present in CNS tumors have been granted. This raises the question of when and for which targets it is meaningful to test in adult patients with CNS tumors. This evidence-based guideline reviews the evidence available for targeted treatment for alterations in the RAS/MAPK pathway (BRAF, NF1), in growth factor receptors (EGFR, ALK, fibroblast growth factor receptor (FGFR), neurotrophic tyrosine receptor kinase (NTRK), platelet-derived growth factor receptor alpha, and ROS1), in cell cycle signaling (CDK4/6, MDM2/4, and TSC1/2) and altered genomic stability (mismatch repair, POLE, high tumor mutational burden (TMB), homologous recombination deficiency) in adult patients with gliomas, glioneuronal and neuronal tumors. At present, targeted treatment for BRAF p.V600E alterations is to be considered part of the standard of care for patients with recurrent gliomas, pending regulatory approval. For approved tumor agnostic treatments for NTRK fusions and high TMB, the evidence for efficacy in adult patients with CNS tumors is very limited, and treatment should preferably be given within prospective clinical registries and trials. For targeted treatment of CNS tumors with FGFR fusions or mutations, clinical trials are ongoing to confirm modest activity so far observed in basket trials. For all other reviewed targets, evidence of benefit in CNS tumors is currently lacking, and testing/treatment should be in the context of available clinical trials.
- Published
- 2023
24. Review of Current Human Genome-Scale Metabolic Models for Brain Cancer and Neurodegenerative Diseases
- Author
-
Ali Kishk, Maria Pires Pacheco, Tony Heurtaux, Lasse Sinkkonen, Jun Pang, Sabrina Fritah, Simone P. Niclou, and Thomas Sauter
- Subjects
brain metabolism ,metabolic modelling ,glioma ,neurodegenerative diseases ,astrocyte ,neuron ,Cytology ,QH573-671 - Abstract
Brain disorders represent 32% of the global disease burden, with 169 million Europeans affected. Constraint-based metabolic modelling and other approaches have been applied to predict new treatments for these and other diseases. Many recent studies focused on enhancing, among others, drug predictions by generating generic metabolic models of brain cells and on the contextualisation of the genome-scale metabolic models with expression data. Experimental flux rates were primarily used to constrain or validate the model inputs. Bi-cellular models were reconstructed to study the interaction between different cell types. This review highlights the evolution of genome-scale models for neurodegenerative diseases and glioma. We discuss the advantages and drawbacks of each approach and propose improvements, such as building bi-cellular models, tailoring the biomass formulations for glioma and refinement of the cerebrospinal fluid composition.
- Published
- 2022
- Full Text
- View/download PDF
25. Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors
- Author
-
Anaïs Oudin, Virginie Baus, Vanessa Barthelemy, Carina Fabian, Eliane Klein, Monika Dieterle, May Wantz, Ann-Christin Hau, Claire Dording, Amandine Bernard, Alessandro Michelucci, Yahaya A. Yabo, Georgia Kanli, Olivier Keunen, Rolf Bjerkvig, Simone P. Niclou, and Anna Golebiewska
- Subjects
Cell Biology ,Cell culture ,Cell isolation ,Cancer ,Model Organisms ,Neuroscience ,Science (General) ,Q1-390 - Abstract
Summary: Tumor organoids and patient-derived orthotopic xenografts (PDOXs) are some of the most valuable pre-clinical tools in cancer research. In this protocol, we describe efficient derivation of organoids and PDOX models from glioma patient tumors. We provide detailed steps for organoid culture, intracranial implantation, and detection of tumors in the brain. We further present technical adjustments for standardized functional assays and drug testing.For complete details on the use and execution of this protocol, please refer to Golebiewska et al. (2020).
- Published
- 2021
- Full Text
- View/download PDF
26. Gender balance and suitable positive actions to promote gender equality among healthcare professionals in neuro-oncology: The EANO positive action initiative
- Author
-
Le Rhun, Emilie, primary, Boele, Florien, additional, Minniti, Giuseppe, additional, Galldiks, Norbert, additional, Taphoorn, Martin, additional, Piil, Karin, additional, Rudà, Roberta, additional, Niclou, Simone P, additional, Geurts, Marjolein, additional, Preusser, Matthias, additional, Weller, Michael, additional, Short, Susan C, additional, and Dirven, Linda, additional
- Published
- 2023
- Full Text
- View/download PDF
27. Formate promotes invasion and metastasis in reliance on lipid metabolism
- Author
-
Delbrouck, Catherine, primary, Kiweler, Nicole, additional, Chen, Oleg, additional, Pozdeev, Vitaly I., additional, Haase, Lara, additional, Neises, Laura, additional, Oudin, Anaïs, additional, Fouquier d’Hérouël, Aymeric, additional, Shen, Ruolin, additional, Schlicker, Lisa, additional, Halder, Rashi, additional, Lesur, Antoine, additional, Schuster, Anne, additional, Lorenz, Nadja I., additional, Jaeger, Christian, additional, Feucherolles, Maureen, additional, Frache, Gilles, additional, Szpakowska, Martyna, additional, Chevigne, Andy, additional, Ronellenfitsch, Michael W., additional, Moussay, Etienne, additional, Piraud, Marie, additional, Skupin, Alexander, additional, Schulze, Almut, additional, Niclou, Simone P., additional, Letellier, Elisabeth, additional, and Meiser, Johannes, additional
- Published
- 2023
- Full Text
- View/download PDF
28. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment
- Author
-
Anne Dirkse, Anna Golebiewska, Thomas Buder, Petr V. Nazarov, Arnaud Muller, Suresh Poovathingal, Nicolaas H. C. Brons, Sonia Leite, Nicolas Sauvageot, Dzjemma Sarkisjan, Mathieu Seyfrid, Sabrina Fritah, Daniel Stieber, Alessandro Michelucci, Frank Hertel, Christel Herold-Mende, Francisco Azuaje, Alexander Skupin, Rolf Bjerkvig, Andreas Deutsch, Anja Voss-Böhme, and Simone P. Niclou
- Subjects
Science - Abstract
Cancer stem cells (CSCs) comprise a putative population that can drive growth and resistance. Here, in glioblastoma models the authors show that rather than being a distinct clonal entity, the CSC population represents a plastic state adoptable by most cancer cells via reversible state transitions induced by the microenvironment.
- Published
- 2019
- Full Text
- View/download PDF
29. Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas
- Author
-
Jean Philippe Nesseler, MD, Dorthe Schaue, PhD, William H. McBride, PhD, DSc, Mi-Heon Lee, PhD, Tania Kaprealian, MD, Simone P. Niclou, PhD, and Philippe Nickers, MD, PhD
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Purpose: Glioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for immunotherapy. However, GBM tends to be nonimmunogenic and exhibits a microenvironment with few or no effector T cells, a relatively low nonsynonymous somatic mutational load, and a low predicted neoantigen burden. GBM also exploits a multitude of immunosuppressive strategies. Methods and Materials: A number of immunotherapeutic approaches have been tested with disappointing results. A rationale exists to combine immunotherapy and radiation therapy, which can induce an immunogenic form of cell death with T-cell activation and tumor infiltration. Results: Various immunotherapy agents, including immune checkpoint modulators, transforming growth factor beta receptor inhibitors, and indoleamine-2,3-dioxygenase inhibitors, have been evaluated with irradiation in preclinical GBM models, with promising results, and are being further tested in clinical trials. Conclusions: This review aims to present the basic rationale behind this emerging complementary therapeutic approach in GBM, appraise the current preclinical and clinical data, and discuss the future challenges in improving the antitumor immune response.
- Published
- 2019
- Full Text
- View/download PDF
30. METABOLIC PATHWAYS
- Author
-
Blough, Michael, Al-Najjar, Mohammad, Stechishin, Owen, Ronen, Sabrina, Weiss, Samuel, Luchman, H, Cairncross, J, Fonkem, Ekokobe, Tobin, Richard, Griffin, Jennifer, Zuzek, Alex, Rogers, Martha, Kathagen, Annegret, Schulte, Alexander, Balcke, Gerd, Phillips, Heidi, Günther, Hauke, Westphal, Manfred, Lamszus, Katrin, Fack, Fred, Bonnel, David, Hochart, Guillaume, Navis, Anna, Wesseling, Pieter, Leenders, William, Stauber, Jonathan, Niclou, Simone, Sahm, Felix, Oezen, Iris, Opitz, Christiane, Radlwimmer, Bernhard, von Deimling, Andreas, Bode, Helge, Ahrendt, Tilman, Adams, Seray, Guillemin, Gilles, Wick, Wolfgang, Platten, Michael, Vartanian, Alenoush, Singh, Sanjay, Burrell, Kelly, Agnihotri, Sameer, Sabha, Nesrin, Zadeh, Gelareh, Teo, Charles, McDonald, Kerrie, Zinger, Anna, Bustamante, Sonia, Lim, Chai, Braidy, Nady, Brew, Bruce, Wolf, Amparo, Lang, Fredrick, Verhaak, Roel, Hawkins, Cynthia, Aldape, Kenneth, Chesnelong, Charles, and Chaumeil, Myriam
- Abstract
The kynurenine pathway (KP) is the principal route of L-Tryptophan (TRP) catabolism leading to the production of kynurenine (KYN), the neuroprotectants, kynurenic acid (KYNA) and picolinic acid (PIC), and the excitotoxic neurotoxin, quinolinic acid (QUIN). The enzymes indoleamine 2,3-dioxygenase-1 (IDO-1), indoleamine 2, 3-dioxygenase-2 (IDO-2) and tryptophan 2,3-dioxygenase (TDO-2) initiate the first step of the KP. Downstream enzymes include kynureninase (KYNU), 3-hydroxyanthranilate 3,4-dioxygenase (3-HAAO), kynurenine hydroxylase (KMO) and 2-amino-3-carboxymuconate semialdehyde decarboxylase (ACMSD). Kynurenine aminotransferase-I (KAT-I) is one of the enzymes responsible for synthesising KYNA. Mounting evidence directly implicates that IDO-1 induction in various tumours is a crucial mechanism facilitating tumour immune evasion and persistence. However, the involvement of the downstream machinery of the KP in brain tumour progression remains unexplored. A complete characterisation of the KP in brain tumours and the role of the KP in maintaining homeostasis between neuroprotection and neurodegeneration in glioma has not yet been investigated. Here we report the first comprehensive characterisation of the KP in cultured human glioma cells and GBM patient plasma. Our qRT-PCR data revealed that interferon-gamma (IFN-γ) (100 IU/ml) stimulation significantly potentiated the expression of IDO-1 IDO-2, KYNU, 3-HAAO, KMO and significantly down-regulated ACMSD and KAT-I expression in cultured human glioma cells. HPLC analysis revealed that IFN-γ stimulation significantly increased KP activity (KYN/TRP ratio), and significantly lowered the KYNA/KYN neuroprotective ratio in human cultured glioma cells. Our HPLC and GCMS data revealed that KP activation was significantly higher and the concentrations of TRP, KYNA, QUIN and PIC and the KYNA/KYN ratio were significantly lower in GBM patient plasma (n = 18) compared to controls. These results provide further evidence for the involvement of the KP in glioma pathophysiology and highlights a potential role of KP products as novel and highly attractive therapeutic targets to evaluate for the treatment of brain tumours.
- Published
- 2013
31. Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy
- Author
-
Eliane Klein, Ann-Christin Hau, Anaïs Oudin, Anna Golebiewska, and Simone P. Niclou
- Subjects
brain tumors ,glioblastoma ,glioma ,immunotherapy ,preclinical models ,organoids ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Malignant brain tumors remain uniformly fatal, even with the best-to-date treatment. For Glioblastoma (GBM), the most severe form of brain cancer in adults, the median overall survival is roughly over a year. New therapeutic options are urgently needed, yet recent clinical trials in the field have been largely disappointing. This is partially due to inappropriate preclinical model systems, which do not reflect the complexity of patient tumors. Furthermore, clinically relevant patient-derived models recapitulating the immune compartment are lacking, which represents a bottleneck for adequate immunotherapy testing. Emerging 3D organoid cultures offer innovative possibilities for cancer modeling. Here, we review available GBM organoid models amenable to a large variety of pre-clinical applications including functional bioassays such as proliferation and invasion, drug screening, and the generation of patient-derived orthotopic xenografts (PDOX) for validation of biological responses in vivo. We emphasize advantages and technical challenges in establishing immunocompetent ex vivo models based on co-cultures of GBM organoids and human immune cells. The latter can be isolated either from the tumor or from patient or donor blood as peripheral blood mononuclear cells (PBMCs). We also discuss the challenges to generate GBM PDOXs based on humanized mouse models to validate efficacy of immunotherapies in vivo. A detailed characterization of such models at the cellular and molecular level is needed to understand the potential and limitations for various immune activating strategies. Increasing the availability of immunocompetent GBM models will improve research on emerging immune therapeutic approaches against aggressive brain cancer.
- Published
- 2020
- Full Text
- View/download PDF
32. AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion
- Author
-
Schuster, Anne, Klein, Eliane, Neirinckx, Virginie, Knudsen, Arnon Møldrup, Fabian, Carina, Hau, Ann-Christin, Dieterle, Monika, Oudin, Anais, Nazarov, Petr V., Golebiewska, Anna, Muller, Arnaud, Perez-Hernandez, Daniel, Rodius, Sophie, Dittmar, Gunnar, Bjerkvig, Rolf, Herold-Mende, Christel, Klink, Barbara, Kristensen, Bjarne Winther, and Niclou, Simone P.
- Published
- 2020
- Full Text
- View/download PDF
33. Increased formate overflow is a hallmark of oxidative cancer
- Author
-
Johannes Meiser, Anne Schuster, Matthias Pietzke, Johan Vande Voorde, Dimitris Athineos, Kristell Oizel, Guillermo Burgos-Barragan, Niek Wit, Sandeep Dhayade, Jennifer P. Morton, Emmanuel Dornier, David Sumpton, Gillian M. Mackay, Karen Blyth, Ketan J. Patel, Simone P. Niclou, and Alexei Vazquez
- Subjects
Science - Abstract
Serine catabolism to formate supplies one-carbon units for biosynthesis. Here the authors show that formate production in murine cancers with high oxidative metabolism exceeds the biosynthetic demand and that high formate levels promotes invasion of cancer cells.
- Published
- 2018
- Full Text
- View/download PDF
34. Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity
- Author
-
Rodius, Sophie, de Klein, Niek, Jeanty, Céline, Sánchez-Iranzo, Héctor, Crespo, Isaac, Ibberson, Mark, Xenarios, Ioannis, Dittmar, Gunnar, Mercader, Nadia, Niclou, Simone P., and Azuaje, Francisco
- Published
- 2020
- Full Text
- View/download PDF
35. Allergic airway inflammation delays glioblastoma progression and reinvigorates systemic and local immunity in mice
- Author
-
Aurélie Poli, Anaïs Oudin, Arnaud Muller, Ilaria Salvato, Andrea Scafidi, Oliver Hunewald, Olivia Domingues, Petr V. Nazarov, Vincent Puard, Virginie Baus, Francisco Azuaje, Gunnar Dittmar, Jacques Zimmer, Tatiana Michel, Alessandro Michelucci, Simone P. Niclou, and Markus Ollert
- Subjects
Immunology ,Immunology and Allergy - Abstract
Numerous patient-based studies have highlighted the protective role of immunoglobulin E-mediated allergic diseases on glioblastoma (GBM) susceptibility and prognosis. However, the mechanisms behind this observation remain elusive. Our objective was to establish a preclinical model able to recapitulate this phenomenon and investigate the role of immunity underlying such protection.An immunocompetent mouse model of allergic airway inflammation (AAI) was initiated before intracranial implantation of mouse GBM cells (GL261). RAG1-KO mice served to assess tumor growth in a model deficient for adaptive immunity. Tumor development was monitored by MRI. Microglia were isolated for functional analyses and RNA-sequencing. Peripheral as well as tumor-associated immune cells were characterized by flow cytometry. The impact of allergy-related microglial genes on patient survival was analyzed by Cox regression using publicly available datasets.We found that allergy establishment in mice delayed tumor engraftment in the brain and reduced tumor growth resulting in increased mouse survival. AAI induced a transcriptional reprogramming of microglia towards a pro-inflammatory-like state, uncovering a microglia gene signature, which correlated with limited local immunosuppression in glioma patients. AAI increased effector memory T-cells in the circulation as well as tumor-infiltrating CD4Our results demonstrate that AAI limits both tumor take and progression in mice, providing a preclinical model to study the impact of allergy on GBM susceptibility and prognosis, respectively. We identify a potentiation of local and adaptive systemic immunity, suggesting a reciprocal crosstalk that orchestrates allergy-induced immune protection against GBM.
- Published
- 2022
36. Comparative analysis of deeply phenotyped GBM cohorts of ‘short-term’ and ‘long-term’ survivors
- Author
-
Archita Biswas, Manuela Salvucci, Kate Connor, Heiko Düssmann, Steven Carberry, Michael Fichtner, Ellen King, Brona Murphy, A.C O’Farrell, Jane Cryan, Alan Beausang, Josephine Heffernan, Mattia Cremona, Bryan T. Hennessy, James Clerkin, Kieron J. Sweeney, Steve MacNally, F Brett, P O’Halloran, Orna Bacon, Simon Furney, Maite Verreault, Emie Quissac, Franck Bielle, Mohammed H Ahmed, Ahmed Idbaih, Sieger Leenstra, Ioannis Ntafoulis, Federica Fabro, Martine Lamfers, Anna Golebiewska, Frank Hertel, Simone P Niclou, Romain Tching Chi Yen, Andreas Kremer, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Diether Lambrechts, Manasa Kalya P, Alexander Kel, Annette T Byrne, and Jochen H.M Prehn
- Subjects
Long term survivors ,Cancer Research ,Cilium ,Neurology ,Oncology ,RNA-sequencing ,Apoptosis ,Neurology (clinical) ,Cell cycle ,Glioblastoma ,Transcriptomics ,Short term survivors ,Reverse phase protein array - Abstract
Background Glioblastoma (GBM) is an aggressive brain cancer that typically results in death in the first 15 months after diagnosis. There have been limited advances in finding new treatments for GBM. In this study, we investigated molecular differences between patients with extremely short (≤ 9 months, Short term survivors, STS) and long survival (≥ 36 months, Long term survivors, LTS). Methods Patients were selected from an in-house cohort (GLIOTRAIN-cohort), using defined inclusion criteria (Karnofsky score > 70; age Results Transcriptomic analysis of tumour samples identified cilium gene signatures as enriched in LTS. Moreover, Immunohistochemical analysis confirmed the presence of cilia in the tumours of LTS. Notably, reverse phase protein array analysis (RPPA) demonstrated increased phosphorylated GAB1 (Y627), SRC (Y527), BCL2 (S70) and RAF (S338) protein expression in STS compared to LTS. Next, we identified 25 unique master regulators (MR) and 13 transcription factors (TFs) belonging to ontologies of integrin signalling and cell cycle to be upregulated in STS. Conclusion Overall, comparison of STS and LTS GBM patients, identifies novel biomarkers and potential actionable therapeutic targets for the management of GBM. Graphical abstract
- Published
- 2023
37. Hub genes in a pan-cancer co-expression network show potential for predicting drug responses [version 2; referees: 2 approved]
- Author
-
Francisco Azuaje, Tony Kaoma, Céline Jeanty, Petr V. Nazarov, Arnaud Muller, Sang-Yoon Kim, Gunnar Dittmar, Anna Golebiewska, and Simone P. Niclou
- Subjects
Research Article ,Articles ,co-expression networks ,network hubs ,drug sensitivity prediction ,anticancer drugs ,transational bioinformatics ,systems biomedicine ,biological networks - Abstract
Background: The topological analysis of networks extracted from different types of “omics” data is a useful strategy for characterizing biologically meaningful properties of the complex systems underlying these networks. In particular, the biological significance of highly connected genes in diverse molecular networks has been previously determined using data from several model organisms and phenotypes. Despite such insights, the predictive potential of candidate hubs in gene co-expression networks in the specific context of cancer-related drug experiments remains to be deeply investigated. The examination of such associations may offer opportunities for the accurate prediction of anticancer drug responses. Methods: Here, we address this problem by: a) analyzing a co-expression network obtained from thousands of cancer cell lines, b) detecting significant network hubs, and c) assessing their capacity to predict drug sensitivity using data from thousands of drug experiments. We investigated the prediction capability of those genes using a multiple linear regression model, independent datasets, comparisons with other models and our own in vitro experiments. Results: These analyses led to the identification of 47 hub genes, which are implicated in a diverse range of cancer-relevant processes and pathways. Overall, encouraging agreements between predicted and observed drug sensitivities were observed in public datasets, as well as in our in vitro validations for four glioblastoma cell lines and four drugs. To facilitate further research, we share our hub-based drug sensitivity prediction model as an online tool. Conclusions: Our research shows that co-expression network hubs are biologically interesting and exhibit potential for predicting drug responses in vitro. These findings motivate further investigations about the relevance and application of our unbiased discovery approach in pre-clinical, translationally-oriented research.
- Published
- 2019
- Full Text
- View/download PDF
38. Hub genes in a pan-cancer co-expression network show potential for predicting drug responses [version 1; referees: 1 approved, 1 approved with reservations]
- Author
-
Francisco Azuaje, Tony Kaoma, Céline Jeanty, Petr V. Nazarov, Arnaud Muller, Sang-Yoon Kim, Gunnar Dittmar, Anna Golebiewska, and Simone P. Niclou
- Subjects
Research Article ,Articles ,co-expression networks ,network hubs ,drug sensitivity prediction ,anticancer drugs ,transational bioinformatics ,systems biomedicine ,biological networks - Abstract
Background: The topological analysis of networks extracted from different types of “omics” data is a useful strategy for characterizing biologically meaningful properties of the complex systems underlying these networks. In particular, the biological significance of highly connected genes in diverse molecular networks has been previously determined using data from several model organisms and phenotypes. Despite such insights, the predictive potential of candidate hubs in gene co-expression networks in the specific context of cancer-related drug experiments remains to be deeply investigated. The examination of such associations may offer opportunities for the accurate prediction of anticancer drug responses. Methods: Here, we address this problem by: a) analyzing a co-expression network obtained from thousands of cancer cell lines, b) detecting significant network hubs, and c) assessing their capacity to predict drug sensitivity using data from thousands of drug experiments. We investigated the prediction capability of those genes using a multiple linear regression model, independent datasets, comparisons with other models and our own in vitro experiments. Results: These analyses led to the identification of 47 hub genes, which are implicated in a diverse range of cancer-relevant processes and pathways. Overall, encouraging agreements between predicted and observed drug sensitivities were observed in public datasets, as well as in our in vitro validations for four glioblastoma cell lines and four drugs. To facilitate further research, we share our hub-based drug sensitivity prediction model as an online tool. Conclusions: Our research shows that co-expression network hubs are biologically interesting and exhibit potential for predicting drug responses in vitro. These findings motivate further investigations about the relevance and application of our unbiased discovery approach in pre-clinical, translationally-oriented research.
- Published
- 2018
- Full Text
- View/download PDF
39. How to move a “fried egg”: membrane blebbing in oligodendrogliomas
- Author
-
Niclou, Simone P, primary and Golebiewska, Anna, additional
- Published
- 2023
- Full Text
- View/download PDF
40. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
- Author
-
Capper, David; https://orcid.org/0000-0003-1945-497X, Reifenberger, Guido, French, Pim J, Schweizer, Leonille; https://orcid.org/0000-0002-4649-2587, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Touat, Mehdi, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Euskirchen, Philipp; https://orcid.org/0000-0002-9138-805X, Haberler, Christine; https://orcid.org/0000-0003-1016-0545, Hegi, Monika E, Brandner, Sebastian; https://orcid.org/0000-0002-9821-0342, Le Rhun, Émilie; https://orcid.org/0000-0002-9408-3278, Rudà, Roberta, Sanson, Marc, Tabatabai, Ghazaleh; https://orcid.org/0000-0002-3542-8782, Sahm, Felix; https://orcid.org/0000-0001-5441-1962, Wen, Patrick Y, Wesseling, Pieter, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, van den Bent, Martin J; https://orcid.org/0000-0001-5710-5127, Capper, David; https://orcid.org/0000-0003-1945-497X, Reifenberger, Guido, French, Pim J, Schweizer, Leonille; https://orcid.org/0000-0002-4649-2587, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Touat, Mehdi, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Euskirchen, Philipp; https://orcid.org/0000-0002-9138-805X, Haberler, Christine; https://orcid.org/0000-0003-1016-0545, Hegi, Monika E, Brandner, Sebastian; https://orcid.org/0000-0002-9821-0342, Le Rhun, Émilie; https://orcid.org/0000-0002-9408-3278, Rudà, Roberta, Sanson, Marc, Tabatabai, Ghazaleh; https://orcid.org/0000-0002-3542-8782, Sahm, Felix; https://orcid.org/0000-0001-5441-1962, Wen, Patrick Y, Wesseling, Pieter, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, and van den Bent, Martin J; https://orcid.org/0000-0001-5710-5127
- Abstract
The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied. Despite that, there is increasing use of advanced molecular diagnostics that identify potential targets, and tumor-agnostic regulatory approvals on targets also present in CNS tumors have been granted. This raises the question of when and for which targets it is meaningful to test in adult patients with CNS tumors. This evidence-based guideline reviews the evidence available for targeted treatment for alterations in the RAS/MAPK pathway (BRAF, NF1), in growth factor receptors (EGFR, ALK, fibroblast growth factor receptor (FGFR), neurotrophic tyrosine receptor kinase (NTRK), platelet-derived growth factor receptor alpha, and ROS1), in cell cycle signaling (CDK4/6, MDM2/4, and TSC1/2) and altered genomic stability (mismatch repair, POLE, high tumor mutational burden (TMB), homologous recombination deficiency) in adult patients with gliomas, glioneuronal and neuronal tumors. At present, targeted treatment for BRAF p.V600E alterations is to be considered part of the standard of care for patients with recurrent gliomas, pending regulatory approval. For approved tumor agnostic treatments for NTRK fusions and high TMB, the evidence for efficacy in adult patients with CNS tumors is very limited, and treatment should preferably be given within prospective clinical registries and trials. For targeted treatment of CNS tumors with FGFR fusions or mutations, clinical trials are ongoing to confirm modest activity so far observed in basket trials. For all other reviewed targets, evidence of benefit in CNS tumors is currently lacking, and testing/treatment should be in the context of available clinical trials.
- Published
- 2023
41. Supplementary Data 3 from A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications
- Author
-
Eric Van Dyck, Simone P. Niclou, Roland Goldbrunner, Christel C. Herold-Mende, Anthony J. Chalmers, Laurent Vallar, Joerg Felsberg, Guido Reifenberger, Marco Timmer, Rolf Warta, Petr V. Nazarov, and Matthieu Gobin
- Abstract
This document contains Supplementary Table S1, which provides the expression data pertaining to the 27-gene signature and relevant clinical data of the Heidelberg cohort.
- Published
- 2023
42. Data from A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications
- Author
-
Eric Van Dyck, Simone P. Niclou, Roland Goldbrunner, Christel C. Herold-Mende, Anthony J. Chalmers, Laurent Vallar, Joerg Felsberg, Guido Reifenberger, Marco Timmer, Rolf Warta, Petr V. Nazarov, and Matthieu Gobin
- Abstract
Inevitable tumor recurrence and a poor median survival are frustrating reminders of the inefficacy of our current standard of care for patients with newly diagnosed glioblastoma (GBM), which includes surgery followed by radiotherapy and chemotherapy with the DNA alkylating agent temozolomide. Because resistance to genotoxic damage is achieved mainly through execution of the DNA damage response (DDR) and DNA repair pathways, knowledge of the changes in DNA repair and cell-cycle gene expression that occur during tumor development might help identify new targets and improve treatment. Here, we performed a gene expression analysis targeting components of the DNA repair and cell-cycle machineries in cohorts of paired tumor samples (i.e., biopsies from the same patient obtained at the time of primary tumor operation and at recurrence) from patients treated with radiotherapy or radiotherapy plus temozolomide. We identified and validated a 27-gene signature that resulted in the classification of GBM specimens into three groups, two of which displayed inverse expression profiles. Each group contained primary and recurrent samples, and the tumor at relapse frequently displayed a gene expression profile different from that of the matched primary biopsy. Within the groups that exhibited opposing gene expression profiles, the expression pattern of the gene signature at relapse was linked to progression-free survival. We provide experimental evidence that our signature exposes group-specific vulnerabilities against genotoxicants and inhibitors of the cell cycle and DDR, with the prospect of personalized therapeutic strategies.Significance: These findings suggest that classification of GBM tumors based on a DNA repair and cell-cycle gene expression signature exposes vulnerabilities to standard-of-care therapies and offers the potential for personalized therapeutic strategies.
- Published
- 2023
43. Supplementary Data 2 from A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications
- Author
-
Eric Van Dyck, Simone P. Niclou, Roland Goldbrunner, Christel C. Herold-Mende, Anthony J. Chalmers, Laurent Vallar, Joerg Felsberg, Guido Reifenberger, Marco Timmer, Rolf Warta, Petr V. Nazarov, and Matthieu Gobin
- Abstract
This document contains Supplementary Figures S1-S6 as well as their Legends. Specifically, Fig. S1: characterization of the 52 gene signature; Fig. S2: Validation of the 27 DNA repair and cell cycle gene signature; Fig. S3: Analysis of the Murat cohort; Fig. S4: Analysis of the TCGA dataset; Fig. S5: Identification of differentially expressed genes and gene ontology analysis of the G1 and G3 groups; Fig. S6: DNA repair and cell-cycle-based strategies for personalized management of GBM".
- Published
- 2023
44. Supplementary Data 1 from A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications
- Author
-
Eric Van Dyck, Simone P. Niclou, Roland Goldbrunner, Christel C. Herold-Mende, Anthony J. Chalmers, Laurent Vallar, Joerg Felsberg, Guido Reifenberger, Marco Timmer, Rolf Warta, Petr V. Nazarov, and Matthieu Gobin
- Abstract
This document details the preliminary differential gene expression analysis carried out using the Köln dataset
- Published
- 2023
45. Supplementary Data 5 from A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications
- Author
-
Eric Van Dyck, Simone P. Niclou, Roland Goldbrunner, Christel C. Herold-Mende, Anthony J. Chalmers, Laurent Vallar, Joerg Felsberg, Guido Reifenberger, Marco Timmer, Rolf Warta, Petr V. Nazarov, and Matthieu Gobin
- Abstract
This document contains Supplementary Table S4, which regroups the differentially expressed genes identified between the G1 and G3 groups of the Wang dataset and the gene ontology terms associated.
- Published
- 2023
46. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment
- Author
-
Dirkse, Anne, Golebiewska, Anna, Buder, Thomas, Nazarov, Petr V., Muller, Arnaud, Poovathingal, Suresh, Brons, Nicolaas H. C., Leite, Sonia, Sauvageot, Nicolas, Sarkisjan, Dzjemma, Seyfrid, Mathieu, Fritah, Sabrina, Stieber, Daniel, Michelucci, Alessandro, Hertel, Frank, Herold-Mende, Christel, Azuaje, Francisco, Skupin, Alexander, Bjerkvig, Rolf, Deutsch, Andreas, Voss-Böhme, Anja, and Niclou, Simone P.
- Published
- 2019
- Full Text
- View/download PDF
47. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
- Author
-
Capper, David, primary, Reifenberger, Guido, additional, French, Pim J, additional, Schweizer, Leonille, additional, Weller, Michael, additional, Touat, Mehdi, additional, Niclou, Simone P, additional, Euskirchen, Philipp, additional, Haberler, Christine, additional, Hegi, Monika E, additional, Brandner, Sebastian, additional, Le Rhun, Emilie, additional, Rudà, Roberta, additional, Sanson, Marc, additional, Tabatabai, Ghazaleh, additional, Sahm, Felix, additional, Wen, Patrick Y, additional, Wesseling, Pieter, additional, Preusser, Matthias, additional, and van den Bent, Martin J, additional
- Published
- 2023
- Full Text
- View/download PDF
48. Analysis of the dynamic co-expression network of heart regeneration in the zebrafish
- Author
-
Sophie Rodius, Anna Fournier, Lou Götz, Robin Liechti, Isaac Crespo, Susanne Merz, Petr V. Nazarov, Niek de Klein, Céline Jeanty, Juan M. González-Rosa, Arnaud Muller, Francois Bernardin, Simone P. Niclou, Laurent Vallar, Nadia Mercader, Mark Ibberson, Ioannis Xenarios, and Francisco Azuaje
- Subjects
Medicine ,Science - Abstract
Abstract The zebrafish has the capacity to regenerate its heart after severe injury. While the function of a few genes during this process has been studied, we are far from fully understanding how genes interact to coordinate heart regeneration. To enable systematic insights into this phenomenon, we generated and integrated a dynamic co-expression network of heart regeneration in the zebrafish and linked systems-level properties to the underlying molecular events. Across multiple post-injury time points, the network displays topological attributes of biological relevance. We show that regeneration steps are mediated by modules of transcriptionally coordinated genes, and by genes acting as network hubs. We also established direct associations between hubs and validated drivers of heart regeneration with murine and human orthologs. The resulting models and interactive analysis tools are available at http://infused.vital-it.ch . Using a worked example, we demonstrate the usefulness of this unique open resource for hypothesis generation and in silico screening for genes involved in heart regeneration.
- Published
- 2016
- Full Text
- View/download PDF
49. Federated learning enables big data for rare cancer boundary detection
- Author
-
Pati, Sarthak, primary, Baid, Ujjwal, additional, Edwards, Brandon, additional, Sheller, Micah, additional, Wang, Shih-Han, additional, Reina, G. Anthony, additional, Foley, Patrick, additional, Gruzdev, Alexey, additional, Karkada, Deepthi, additional, Davatzikos, Christos, additional, Sako, Chiharu, additional, Ghodasara, Satyam, additional, Bilello, Michel, additional, Mohan, Suyash, additional, Vollmuth, Philipp, additional, Brugnara, Gianluca, additional, Preetha, Chandrakanth J., additional, Sahm, Felix, additional, Maier-Hein, Klaus, additional, Zenk, Maximilian, additional, Bendszus, Martin, additional, Wick, Wolfgang, additional, Calabrese, Evan, additional, Rudie, Jeffrey, additional, Villanueva-Meyer, Javier, additional, Cha, Soonmee, additional, Ingalhalikar, Madhura, additional, Jadhav, Manali, additional, Pandey, Umang, additional, Saini, Jitender, additional, Garrett, John, additional, Larson, Matthew, additional, Jeraj, Robert, additional, Currie, Stuart, additional, Frood, Russell, additional, Fatania, Kavi, additional, Huang, Raymond Y., additional, Chang, Ken, additional, Balaña, Carmen, additional, Capellades, Jaume, additional, Puig, Josep, additional, Trenkler, Johannes, additional, Pichler, Josef, additional, Necker, Georg, additional, Haunschmidt, Andreas, additional, Meckel, Stephan, additional, Shukla, Gaurav, additional, Liem, Spencer, additional, Alexander, Gregory S., additional, Lombardo, Joseph, additional, Palmer, Joshua D., additional, Flanders, Adam E., additional, Dicker, Adam P., additional, Sair, Haris I., additional, Jones, Craig K., additional, Venkataraman, Archana, additional, Jiang, Meirui, additional, So, Tiffany Y., additional, Chen, Cheng, additional, Heng, Pheng Ann, additional, Dou, Qi, additional, Kozubek, Michal, additional, Lux, Filip, additional, Michálek, Jan, additional, Matula, Petr, additional, Keřkovský, Miloš, additional, Kopřivová, Tereza, additional, Dostál, Marek, additional, Vybíhal, Václav, additional, Vogelbaum, Michael A., additional, Mitchell, J. Ross, additional, Farinhas, Joaquim, additional, Maldjian, Joseph A., additional, Yogananda, Chandan Ganesh Bangalore, additional, Pinho, Marco C., additional, Reddy, Divya, additional, Holcomb, James, additional, Wagner, Benjamin C., additional, Ellingson, Benjamin M., additional, Cloughesy, Timothy F., additional, Raymond, Catalina, additional, Oughourlian, Talia, additional, Hagiwara, Akifumi, additional, Wang, Chencai, additional, To, Minh-Son, additional, Bhardwaj, Sargam, additional, Chong, Chee, additional, Agzarian, Marc, additional, Falcão, Alexandre Xavier, additional, Martins, Samuel B., additional, Teixeira, Bernardo C. A., additional, Sprenger, Flávia, additional, Menotti, David, additional, Lucio, Diego R., additional, LaMontagne, Pamela, additional, Marcus, Daniel, additional, Wiestler, Benedikt, additional, Kofler, Florian, additional, Ezhov, Ivan, additional, Metz, Marie, additional, Jain, Rajan, additional, Lee, Matthew, additional, Lui, Yvonne W., additional, McKinley, Richard, additional, Slotboom, Johannes, additional, Radojewski, Piotr, additional, Meier, Raphael, additional, Wiest, Roland, additional, Murcia, Derrick, additional, Fu, Eric, additional, Haas, Rourke, additional, Thompson, John, additional, Ormond, David Ryan, additional, Badve, Chaitra, additional, Sloan, Andrew E., additional, Vadmal, Vachan, additional, Waite, Kristin, additional, Colen, Rivka R., additional, Pei, Linmin, additional, Ak, Murat, additional, Srinivasan, Ashok, additional, Bapuraj, J. Rajiv, additional, Rao, Arvind, additional, Wang, Nicholas, additional, Yoshiaki, Ota, additional, Moritani, Toshio, additional, Turk, Sevcan, additional, Lee, Joonsang, additional, Prabhudesai, Snehal, additional, Morón, Fanny, additional, Mandel, Jacob, additional, Kamnitsas, Konstantinos, additional, Glocker, Ben, additional, Dixon, Luke V. M., additional, Williams, Matthew, additional, Zampakis, Peter, additional, Panagiotopoulos, Vasileios, additional, Tsiganos, Panagiotis, additional, Alexiou, Sotiris, additional, Haliassos, Ilias, additional, Zacharaki, Evangelia I., additional, Moustakas, Konstantinos, additional, Kalogeropoulou, Christina, additional, Kardamakis, Dimitrios M., additional, Choi, Yoon Seong, additional, Lee, Seung-Koo, additional, Chang, Jong Hee, additional, Ahn, Sung Soo, additional, Luo, Bing, additional, Poisson, Laila, additional, Wen, Ning, additional, Tiwari, Pallavi, additional, Verma, Ruchika, additional, Bareja, Rohan, additional, Yadav, Ipsa, additional, Chen, Jonathan, additional, Kumar, Neeraj, additional, Smits, Marion, additional, van der Voort, Sebastian R., additional, Alafandi, Ahmed, additional, Incekara, Fatih, additional, Wijnenga, Maarten M. J., additional, Kapsas, Georgios, additional, Gahrmann, Renske, additional, Schouten, Joost W., additional, Dubbink, Hendrikus J., additional, Vincent, Arnaud J. P. E., additional, van den Bent, Martin J., additional, French, Pim J., additional, Klein, Stefan, additional, Yuan, Yading, additional, Sharma, Sonam, additional, Tseng, Tzu-Chi, additional, Adabi, Saba, additional, Niclou, Simone P., additional, Keunen, Olivier, additional, Hau, Ann-Christin, additional, Vallières, Martin, additional, Fortin, David, additional, Lepage, Martin, additional, Landman, Bennett, additional, Ramadass, Karthik, additional, Xu, Kaiwen, additional, Chotai, Silky, additional, Chambless, Lola B., additional, Mistry, Akshitkumar, additional, Thompson, Reid C., additional, Gusev, Yuriy, additional, Bhuvaneshwar, Krithika, additional, Sayah, Anousheh, additional, Bencheqroun, Camelia, additional, Belouali, Anas, additional, Madhavan, Subha, additional, Booth, Thomas C., additional, Chelliah, Alysha, additional, Modat, Marc, additional, Shuaib, Haris, additional, Dragos, Carmen, additional, Abayazeed, Aly, additional, Kolodziej, Kenneth, additional, Hill, Michael, additional, Abbassy, Ahmed, additional, Gamal, Shady, additional, Mekhaimar, Mahmoud, additional, Qayati, Mohamed, additional, Reyes, Mauricio, additional, Park, Ji Eun, additional, Yun, Jihye, additional, Kim, Ho Sung, additional, Mahajan, Abhishek, additional, Muzi, Mark, additional, Benson, Sean, additional, Beets-Tan, Regina G. H., additional, Teuwen, Jonas, additional, Herrera-Trujillo, Alejandro, additional, Trujillo, Maria, additional, Escobar, William, additional, Abello, Ana, additional, Bernal, Jose, additional, Gómez, Jhon, additional, Choi, Joseph, additional, Baek, Stephen, additional, Kim, Yusung, additional, Ismael, Heba, additional, Allen, Bryan, additional, Buatti, John M., additional, Kotrotsou, Aikaterini, additional, Li, Hongwei, additional, Weiss, Tobias, additional, Weller, Michael, additional, Bink, Andrea, additional, Pouymayou, Bertrand, additional, Shaykh, Hassan F., additional, Saltz, Joel, additional, Prasanna, Prateek, additional, Shrestha, Sampurna, additional, Mani, Kartik M., additional, Payne, David, additional, Kurc, Tahsin, additional, Pelaez, Enrique, additional, Franco-Maldonado, Heydy, additional, Loayza, Francis, additional, Quevedo, Sebastian, additional, Guevara, Pamela, additional, Torche, Esteban, additional, Mendoza, Cristobal, additional, Vera, Franco, additional, Ríos, Elvis, additional, López, Eduardo, additional, Velastin, Sergio A., additional, Ogbole, Godwin, additional, Soneye, Mayowa, additional, Oyekunle, Dotun, additional, Odafe-Oyibotha, Olubunmi, additional, Osobu, Babatunde, additional, Shu’aibu, Mustapha, additional, Dorcas, Adeleye, additional, Dako, Farouk, additional, Simpson, Amber L., additional, Hamghalam, Mohammad, additional, Peoples, Jacob J., additional, Hu, Ricky, additional, Tran, Anh, additional, Cutler, Danielle, additional, Moraes, Fabio Y., additional, Boss, Michael A., additional, Gimpel, James, additional, Veettil, Deepak Kattil, additional, Schmidt, Kendall, additional, Bialecki, Brian, additional, Marella, Sailaja, additional, Price, Cynthia, additional, Cimino, Lisa, additional, Apgar, Charles, additional, Shah, Prashant, additional, Menze, Bjoern, additional, Barnholtz-Sloan, Jill S., additional, Martin, Jason, additional, and Bakas, Spyridon, additional
- Published
- 2022
- Full Text
- View/download PDF
50. Revealing and Harnessing Tumour-Associated Microglia/Macrophage Heterogeneity in Glioblastoma
- Author
-
Yolanda Pires-Afonso, Simone P. Niclou, and Alessandro Michelucci
- Subjects
glioblastoma ,tumour-associated microglia/macrophages ,cellular heterogeneity ,immunotherapy ,precision medicine ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Cancer heterogeneity and progression are subject to complex interactions between neoplastic cells and their microenvironment, including the immune system. Although glioblastomas (GBMs) are classified as ‘cold tumours’ with very little lymphocyte infiltration, they can contain up to 30−40% of tumour-associated macrophages, reported to contribute to a supportive microenvironment that facilitates tumour proliferation, survival and migration. In GBM, tumour-associated macrophages comprise either resident parenchymal microglia, perivascular macrophages or peripheral monocyte-derived cells. They are recruited by GBMs and in turn release growth factors and cytokines that affect the tumour. Notably, tumour-associated microglia/macrophages (TAMs) acquire different expression programs, which shape the tumour microenvironment and contribute to GBM molecular subtyping. Further, emerging evidence highlights that TAM programs may adapt to specific tumour features and landscapes. Here, we review key evidence describing TAM transcriptional and functional heterogeneity in GBM. We propose that unravelling the intricate complexity and diversity of the myeloid compartment as well as understanding how different TAM subsets may affect tumour progression will possibly pave the way to new immune therapeutic avenues for GBM patients.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.